



MEMORANDUM

Agenda Item 15(C)1

TO: Honorable Chairperson Dennis C. Moss and
Members, Board of County Commissioners

DATE: April 21, 2009

FROM: Honorable Harvey Ruvin, Clerk
Circuit and County Courts

SUBJECT: Appointment of
Pascal J. Goldschmidt, M.D.
to the Health Council of South
Florida, Inc.

Kay Sullivan, Director
Clerk of the Board Division

It is recommended that the Board consider the appointment Dr. Pascal J. Goldschmidt to the Health Council of South Florida for a period of two years, as recommended by the Health Council of South Florida, Inc. Nominating Committee.

In accordance with Florida Statutes 408.033, the Health Council of South Florida, Inc. Nominating Committee has submitted the application and resume of Dr. Goldschmidt as a qualified candidate for appointment to fill the seat to be vacated by Melvin Fletcher on May 22, 2009. Florida Statutes provide for the county commission having jurisdiction in the respective district to appoint the members to the Council.

Attached for your information and review is a copy of the application, resume and the letter of nomination for Dr. Goldschmidt.

KMS:sm

Attachments



Officers

Albert Collazo
Chair

Jose Perdomo, M.H.S.A., J.D.
Vice Chair

Ed Rosasco, FACHE
Treasurer

Debra S. Walker, Ph.D.
Secretary

Board Members

Kim Bassett

Melvyn Fletcher, M.D., F.A.A.P.

Rev. Dr. Ted Greer, Jr.

Nelson Lazo

Fermin Leguen, M.D.

Kerry Shelby, C.P.A.

Fred Stock, M.S.W., L.N.H.A.

Honorary Board Member

Hon. Carlos Alvarez
Mayor, Miami-Dade County

President & CEO

Marisel Losa, M.H.S.A.

An Equal
Opportunity
Employer

March 27, 2009

Shania Moore
Office of the Clerk of the Board
Dade County Board of County Commissioners
111 N.W. 1st Street, Suite 17202
Miami, Florida 33128

Dear Ms. Moore:

The Health Council of South Florida Inc. (Council) is pleased to submit the application of Pascal J. Goldschmidt, M.D. to the Board of Directors in the category of Purchaser for a two year term. The seat became vacant with the resignation of K.K. Bentil (consumer >60) and the category reassignment of Melvin Fletcher (previously a purchaser and now, due to his retirement to private life & age, a consumer >60). The Council's Nominating Committee convened to review applications in accordance with Council Bylaws and recommends the appointment of Dr. Goldschmidt to the Council's Board of Directors. Dr. Goldschmidt's application form and resume are attached.

If possible, we respectfully request that this application be submitted to the Commissioners for appointment at the next County Commission Meeting. Please feel free to contact me, or Wendy Sejour, Manager, Operational Affairs, at 305-592-1452, ext. 116 should you need any additional information.

Sincerely,

Marisel Losa
President & Chief Executive Officer

enclosure

8095 NW 12th Street, Suite 300 - Doral, FL 33126

Phone 305-592-1452 - Fax 305-592-0981 - Web www.healthcouncil.org - Email healthcouncil@healthcouncil.org

Our Mission is to be the source of unbiased health data, quality program planning, management and evaluation, strong community partnerships in Miami-Dade and Monroe Counties and targeted healthcare policy at the local, state, and national levels.

Please note: Applicants must reside in Miami-Dade County

CANDIDATE FOR NOMINATION TO SERVE ON THE LOCAL HEALTH COUNCIL
DISTRICT XI, MIAMI-DADE COUNTY

NAME PASCAL J. GOLDSCHMIDT, M.D.
BUSINESS ADDRESS P.O. Box 016099 (R-699) TEL 305 243 6545
(Street)
MIAMI, FLA. 33101 FAX 305 243 4888
(City, State Zip Code)
BUSINESS EMAIL PGOLDSCHMIDT@MED.MIAMI.EDU

RESIDENCE ADDRESS 4941 SW 75 LANE TEL 305 284 1182
(Street)
MIAMI FLA. 33143 FAX _____
(City, State Zip Code)

MALE FEMALE _____ BLACK _____ CAUCASIAN OTHER _____ HISPANIC _____ AGE 60 OR OLDER _____

TYPE OF SEAT: PURCHASER _____; PROVIDER ; CONSUMER _____


EMPLOYER UNIVERSITY OF MIAMI

NATURE OF BUSINESS/PROFESSION Healthcare

IF CORPORATION, INDICATE TITLE & DUTIES _____

PERTINENT BIOGRAPHICAL INFORMATION (Resume or Curriculum Vitae may be attached)

I, (candidate's name) PASCAL GOLDSCHMIDT, a citizen of the United States, and a duly qualified elector of Miami-Dade County, would, if appointed, be willing and able to discharge the responsibilities and functions of a member of the Local Health Council. I declare that I do not serve on another board, agency or advisory group created and/or funded by the Miami-Dade County Commission.


CANDIDATE'S SIGNATURE

3.25.09
DATE

Biography
Pascal J. Goldschmidt, M.D.

Pascal J. Goldschmidt, M.D., an internationally renowned cardiologist, became senior vice president for medical affairs and dean of the University of Miami Leonard M. Miller School of Medicine in April 2006. He has overseen tremendous growth not only on the medical campus in Miami, with the recent purchase of Cedars Medical Center which is now University of Miami Hospital, but also in Palm Beach County

with the expansion of the Miller School of Medicine at Florida Atlantic University and the establishment of new clinical practices and proposed residency training programs.

Global health and research initiatives include the new International Medicine Institute in Latin America and the Global Initiative for Community Health and Development. Dean Goldschmidt has also created The Miami Institute for Human Genomics and the Interdisciplinary Stem Cell Institute, both headed by newly recruited, world-renowned researchers.

Dr. Goldschmidt, whose research applies genomics and cell therapy to the prevention, diagnosis and treatment of coronary artery disease, was previously chairman of the Department of Medicine at Duke University Medical Center. Before taking the chairman's role, he served as chief of Duke's Division of Cardiology.

Before joining the Duke faculty in 2000 he was director of cardiology at The Ohio State University College of Medicine and Public Health, where he built the Heart and Lung Research Institute and a heart hospital.

A native of Belgium, Dr. Goldschmidt received his medical degree from the Universite Libre de Bruxelles and completed residency and fellowship training in Brussels at Erasme Academic Hospital and in the United States at The Johns Hopkins University. Following his training at Hopkins, he served as an associate professor in the university's Department of Cell Biology and Anatomy, Department of Pathology, and Division of Cardiology in the Department of Medicine until 1997.



CURRICULUM VITAE

Date: March 6, 2008

I. PERSONAL

Name: **Pascal J. Goldschmidt, MD, FACC**

Office Phone: (305) 243-6545

Home Address: 4941 SW 75 Lane
Miami, FL 33143

Current Academic Rank: Professor of Medicine

Current Track of Appointment: Tenured

Primary Department: Medicine

Secondary or Joint Appointments:

Citizenship: US citizenship (born in Brussels, Belgium)
Naturalized August 27, 2002

II. HIGHER EDUCATION

Universite Libre de Bruxelles, Brussels, Belgium
Bachelor Science in Biochemistry, Magna cum Laude
Oct 1972 – Sept 1976

Universite Libre de Bruxelles, Brussels, Belgium
MD, Suma Cum Laude, valedictorian
Oct 1976 – June 1980

Erasme Academic Hospital, University Libre de Bruxelles, Brussels, Belgium
Intern and Resident in Medicine/Cardiology
Oct 1980 – Sept 1983

Medical University of South Carolina, Charleston, SC
Research Fellow, Department of Immunology, and Microbiology
May 1983 – June 1986

Union Memorial Hospital, Baltimore, MD
Resident in Medicine
July 1986 – June 1988

John Hopkins University, Baltimore, MD
Clinical Fellow in Cardiology
Research Fellow in Cell Biology and Anatomy
July 1988 – June 1991

Board Certification: Internal medicine #118032

Medical Licensure: Florida (2006- present)
North Carolina (2000 – Present)
Maryland (1998 – 2006)
Ohio (1997 – 2007)

III. EXPERIENCE**Academic:**

- 2006 – Present University of Miami, Miller School of Medicine
Senior Vice President of Medical Affairs and Dean
Professor of Medicine
- 2000 - 2006 Duke University Medical Center
Edward S. Orgain Professor of Cardiology
Professor of Medicine
Professor of Genetics
Professor of Cell Biology
Professor of Pathology
- 2000 - Present Universite Libre de Bruxelles
Honorary Consulting Professor of Cardiology
Brussels, Belgium
- 1997 - 2000 The Ohio State University, College of Medicine and Public Health,
Cardiology Division,
Professor of Internal Medicine, Cell Biology, and Genetics
- 1996 - 1997 Johns Hopkins University School of Medicine
Department of Pathology
Associate Professor
- 1994 - 1997 Johns Hopkins University School of Medicine
Associate Professor,
Department of Medicine, Cardiology Division, Department of Cell
Biology and Anatomy
- 1991 - 1994 Johns Hopkins University School of Medicine
Assistant Professor
Department of Medicine, Cardiology Division,
Department of Cell Biology and Anatomy

Hospital and Administrative Appointments:

- 2007 – Present UHealth System
Chief Executive Officer
- 2006 – Present University of Miami, Miller School of Medicine
Senior Vice President for Medical Affairs and Dean
- 2003 – 2006 Duke University Medical Center
Chair, Department of Medicine
- 2000 – 2006 Duke Cardiovascular Center for Genomic Science
Director
- 2000 - 2003 Duke University Medical Center
Chief, Division of Cardiology
- 1998 - 2000 The Ohio State University Hospitals
Director, Division of Cardiology

Pascal J. Goldschmidt, M.D.
1997 – 2000

Page 3

3/27/2009

The Ohio State University, College of Medicine and Public Health,
Department of Internal Medicine,
John H. and Mildred C. Lumley Chair in Medicine

1997 - 2000

The Ohio State University Hospitals
Director, Heart and Lung Institute

1994 - 1997

Co-Director, Thrombosis Center

1991 - 1997

Co-Director, The Henry Ciccarone Center for
The Prevention of Heart Disease

1991 - 1997

Director, Bernard Vascular Biology Laboratory

1991 - 1997

Johns Hopkins University
Attending, Coronary Care Unit

Consulting Positions:

2005 -- 2006

Bristol-Myers Squibb, Merck, Imedd, Novartis, Sanofi, Eli-Lilly

2002 – 2003

The Sarnoff Endowment for Cardiovascular Science, Great Falls,
VA
Chair Scientific Board

2001 – 2002

The Sarnoff Endowment for Cardiovascular Science, Great Falls,
VA
Vice-Chair Scientific Board

2001 - 2002

Doris Duke Charitable Foundation, New York, NY
Member Review Panel

1996 – 1998

CardioGenesis Corporation, Palo Alto, CA
Member, Scientific Advisory Board

1996 – 1998

American Pharmaceutical, Inc., Palo Alto, CA
Member, Scientific Advisory Board, Otsuka

IV. PUBLICATIONS

Book Sections:

1. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Lee WM. In: **Vitamin D; Chemical, Biochemical and Clinical Update** (A.W. Norman, K.Schaefer, H.-G. Grigoleit and D.V. Herrath, eds.) Walter De Gruyter & Co., Berlin, pp. 1103-1104. Evidence of circulating Gc: actin complexes in health and disease, 1985.
2. Nel AE, Petrini M, Emerson DL, Goldschmidt-Clermont PJ, Galbraith RM. In: **Vitamin D; Chemical, Biochemical, and Clinical Update** (A.W. Norman, K.Schaefer, H.-G. Grigoleit and D.V. Herrath, eds.) Walter De Gruyter & Co., Berlin, pp. 691-692. Altered configuration of D-binding protein (Gc) on membranes of abnormal and malignant B lymphocytes, 1985.
3. Goldschmidt-Clermont PJ, Arnaud P, Galbraith RM. In: **Protides of the biological fluids** (H. Peeters, ed.) Pergamon Press, New York, pp. 899-901. Interaction of Gc (Vitamin D-binding protein) with G-actin or proteolytic fragments of actin causes similar alteration in IEF profile, 1986.
4. Pollard TD, Magnus A, Doberstein SK, Goldschmidt-Clermont PJ, Kaiser DA, Machesky LM, Maciver S, Rimm DL, Wachsstock D. In: **Springer Series in Biophysics, Cytoskeletal and Extracellular**

- Proteins** (U. Aebi and J. Engel, eds.) London, pp. 271-279. Structure-function studies of the actin filament system of *Acanthamoeba*, 1989.
5. Goldschmidt-Clermont PJ. In: **The Johns Hopkins Medical Grand Rounds** (P.A. Murphy and J.J. Harden eds.) Vol. XIX, pp. 17-24. Myocardial infarction: coronary artery thrombosis or spasm, 1993.
 6. Goldschmidt-Clermont PJ. In: **Guidebook to the Cytoskeletal and Motor Proteins** (R.D. Vale and T. Kreis, eds.) pp. 92-94. Vitamin D Binding/Gc protein, 1993.
 7. Heldman AW, and Goldschmidt-Clermont PJ. In: **Cell Adhesion and Motility** (R.M. Warn, ed.) pp317-324. Cell signaling and motile response, 1993.
 8. Crawford LE, Tucker RW, Goldschmidt-Clermont PJ. In: **Actin: Biophysics, Biochemistry and Cell Biology** (J.E. Estes and P.J. Higgins, eds.) pp 105-112. Actin regulation and surface catalysis, 1994.
 9. Heldman AW, Furman MI, Goldschmidt-Clermont PJ. In: **Molecular Basis of Medicine** (C.V. Dang and A.M. Feldman, eds.) Mosby-Year Book, Inc., St. Louis. Coronary Artery Disease and atherogenesis, 1995.
 10. Blumenthal RS, Calkins H, Goldschmidt-Clermont PJ. In: **Cardiac Arrest. The Science and Practice of Resuscitation Medicine** (N.A. Paradis, H.R. Halperin and R.M. Novak, eds.) Williams and Wilkins, Baltimore. Pp 353-369. Prevention of sudden cardiac death, 1995.
 11. Kandzari DE, Chen J, Goldschmidt-Clermont PJ. In: **Subcellular Biochemistry (vol. 26): myo-Inositol Phosphates, Phosphoinositides and Signal Transduction**. (B.B. Biswas and S. Biswas, eds.) Plenum Press, New York. Regulation of the actin cytoskeleton by inositol phospholipid pathways, 1996.
 12. Moldovan L, Goldschmidt-Clermont PJ. In: **Dynamical Networks in Physics and Biology**. Of Proteins, Redox States and Living Things, 1999.
 13. Hassanain H and Goldschmidt-Clermont PJ. In: **Antioxidant and Redox Regulation of Genes**. Academic Press. (C. Sen ed.) pp 47-79. Rac, Superoxide, and Signal Transduction, 1999.
 14. Marsh, C.B., Kelley, T.W., Graham, M.M., Dong, C., Goldschmidt-Clermont PJ. Monocytes may regulate tissue fibrosis: Role of reactive oxygen species in monocyte survival and in the activation of latent transforming growth factor- β (2001) **Chest**, 120 (SUPPL.), pp. 15S-16S.
 15. Goldschmidt-Clermont PJ, Lopes N, Crawford LE. In: **Platelets (Professional/Scholarly Publishing (PSP) Division of American Publishers AAP/PSP 2002 Award Winner for the Best Book in Medical Science)**. Academic Press/Elsevier Science (A. Michelson ed.) pp 375-398. Atherosclerosis and Coronary Artery Disease, 2002.
 16. Kereiakes DJ and Goldschmidt-Clermont PJ. In: **Contemporary Cardiology: Platelet Glycoprotein IIB/IIIa Inhibitors In Cardiovascular Disease, 2nd Edition**. (MA Lincoff ed.) pp 383-396. Humana Press, Torowa, NJ, 2002.

Monographs:

1. Lincoff AM, Engel SS (co-eds), Bhatt DL, Goldschmidt-Clermont PJ, Marso SP, McGuire DK. Diabetes and Cardiovascular Disease: The Role of the Glycoprotein IIB/IIIa Inhibitors. Presented at Eli Lilly Advisory Board Meeting, Atlanta, GA, February 6, 2002.
2. Lepor NE, Kandzari DE, Goldschmidt-Clermont PJ, Kereiakes DJ, Marmur JD, Vetrovec GW. Report Card on the Pharmacologic Management of Coronary Artery Disease in the Catheterization Laboratory. Presented at Eli Lilly meeting, Chicago, IL, June 12, 2004.

Articles:

1. Désir D, Féry F, Goldschmidt-Clermont P, Goldschmidt D, Van Gansbeke D, Verhoeven A. [Clinical applications of an extracorporeal pancreas] [Article in French] *Brux Med*. 1979 Nov-Dec;59(11-12):497-502.
2. Graff GL, Gueuning C, Glupczynski Y, Goldschmidt P. Systemic effects of colchicine on phosphate metabolism in innervated and denervated, slow and fast muscles of the rat. *Arch Internat Physiol Biochim* 88:393-405, 1980.
3. Goldschmidt P, Glupczynski Y, Gueuning C, Graff GL. Systemic effects of podophyllotoxin on phosphate metabolism in innervated and denervated, slow and fast muscles of the rat. *Arch Internat Physiol Biochim* 88:465-74, 1980.
4. Nel AE, Landreth GE, Goldschmidt-Clermont PJ, Tung HE, Galbraith RM. Enhanced tyrosine phosphorylation in B lymphocytes upon complexing of membrane immunoglobulin. *Biochem Biophys Res Comm* 125:859-866, 1984.
5. Goldschmidt-Clermont P, Petrini M, Khansari N, Fudenberg HH. The role of PNP enzyme in autologous rosette-forming cells. *Cell Immunol* 87(2): 340-347, 1984.
6. Khansari N, Petrini M, Ambrogi F, Goldschmidt-Clermont P, Fudenberg HH. Role of autorosette forming cells in antibody synthesis in vitro: suppressive activity of ARFC in humoral immune response. *Immunobiology* 166(1): 1-11, 1984.
7. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Werner PM. Effect of ligand binding upon measurement of Gc by rocket immunoelectrophoresis: implications for protein determination and for studies of protein/ligand interaction. *Electrophoresis* 6:155-161, 1985.
8. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Werner PM, Nel AM, Lee WM. Accurate quantitation of native Gc in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis. *Clin Chim Acta*, 148:173-183, 1985.
9. Lee WM, Emerson DL, Werner PM, Arnaud P, Goldschmidt-Clermont P, Galbraith RM. Decreased serum group specific component protein levels and complexes with actin in fulminant hepatic necrosis. *Hepatology* 5:271-275, 1985.
10. Nel AE, Navailles M, Emerson DL, Goldschmidt-Clermont P, Pathak SK, Tsang KY, Galbraith RM. Altered configuration of Gc on the plasma membrane of transformed and malignant human B lymphocytes. *Clin Immunol Immunopathol* 37:191-202, 1985.
11. Nel AE, Wooten MW, Goldschmidt-Clermont PJ, Miller PJ, Stevenson HC, Galbraith RM. Polymyxin B causes coordinate inhibition of phorbol ester-induced C-Kinase activity and proliferation of B lymphocytes. *Biochem Biophys Res Comm* 128:1364-1372, 1985.
12. Nel AE, Navailles M, Rosberger DF, Landreth GE, Goldschmidt-Clermont PJ, Baldwin GJ, Galbraith RM. Phorbol ester induces tyrosine phosphorylation in normal and abnormal human B lymphocytes. *J Immunol* 135:3448-345, 1985.
13. Wooten MW, Nel AE, Goldschmidt-Clermont PJ, Galbraith RM, Wrenn RW. Identification of a major endogenous substrate for phospholipid/Ca²⁺-dependent kinase in pancreatic acini as Gc (Vitamin D-binding protein). *FEBS Lett* 191:97-101, 1985.
14. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Marsot F, Nel AE, Arnaud P. Distinct sites on the G-actin molecule bind group-specific component and deoxyribonuclease I. *Biochem J* 228:471-477, 1985.

15. Nel AE, Wooten MW, Landreth GE, Goldschmidt-Clermont PJ, Stevenson HC, Miller PJ, Galbraith RM. Translocation of phospholipid/Ca²⁺-dependent protein kinase in B lymphocytes activated by phorbol ester or crosslinking of membranes immunoglobulin. **Biochem J** 233:145-149, 1986.
16. Goldschmidt-Clermont PJ, Allen PC, Nel AE, Emerson DL, Day JR, Galbraith RM. Gc (Vitamin D-binding protein) binds the 33.5 K tryptic fragment of actin. **Life Sci** 38:735-742, 1986.
17. Miribel L, Goldschmidt-Clermont P, Galbraith RM, Arnaud P. Rapid purification of native group-specific component (Vitamin D-binding protein) by differential affinity for immobilized triazine dyes. **J Chromatogr** 363:448-455, 1986.
18. Goldschmidt-Clermont PJ, Van Alstyne EL, Day JR, Nel AE, Emerson DL, Lazarchick J, Galbraith RM. Group-specific component (vitamin D-binding protein) prevents the interaction between G-actin and profilin. **Biochemistry** 25:6467-6472, 1986.
19. Krayner JW, Emerson DL, Goldschmidt-Clermont PJ, Nel AE, Werner PA, Galbraith RM. Qualitative and quantitative studies of Gc (Vitamin D-binding protein) in saliva from normals and patients with periodontal disease. **J Periodont Res** 22:259-263, 1987.
20. Katikaneni LP, Emerson DL, Goldschmidt-Clermont PJ, Loadholt BL, Levkoff AH, Galbraith RM. High levels of group specific component (vitamin D-binding protein) in the cerebrospinal fluid of infant aged less than two months. **Biol Neonate** 52:250-255, 1987.
21. Young WO, Goldschmidt-Clermont PJ, Lee WM, Emerson DL, Jollow DJ, Galbraith RM. Correlation between extent of liver damage in fulminant hepatic necrosis and complexing of circulating Gc (vitamin D-binding protein). **J Lab Clin Med** 110:83-90, 1987.
22. Lee WM, Emerson DL, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Galbraith RM. Diminished serum Gc (vitamin D-binding protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis (FHN). **Hepatology** 7:825-830, 1987.
23. Goldschmidt-Clermont PJ, Williams MH, Galbraith RM. Altered conformation of Gc (vitamin D-binding protein) upon complexing with cellular actin. **Biochem Biophys Res Comm** 146:611-617, 1987.
24. Goldschmidt-Clermont PJ, Lee WM, Galbraith RM. Proportion of circulating Gc (vitamin D-binding protein) in complexed form: relation to clinical outcome in fulminant hepatic necrosis. **Gastroenterology** 94:1454-1458, 1988.
25. Goldschmidt-Clermont PJ, Van Baelen H, Bouillon R, Shook TE, Williams MH, Nel AE, Galbraith RM. Role of group specific component (vitamin D-binding protein) in clearance of actin from the circulation in the rabbit. **J Clin Invest** 81:1519-1527, 1988.
26. Kaiser DA, Goldschmidt-Clermont PJ, Levine BA, Pollard TD. Characterization of renatured profilin purified by urea elution from poly-l-proline agarose columns. **Cell Motility and Cytoskeleton** 14:251-262, 1989.
27. Goldschmidt-Clermont PJ, Machesky LM, Baldassare JJ, Pollard TD. The actin-binding protein profilin binds to PIP₂ and inhibits its hydrolysis by phospholipase-C. **Science** 247:1575-1578, 1990.
28. Machesky LM, Goldschmidt-Clermont PJ, Pollard TD. The affinities of human platelet and *Acanthamoeba* profilin isoforms for polyphosphoinositides account for their relative abilities to inhibit phospholipase C. **Cell Regulation** 1:937-950, 1990.
29. Goldschmidt-Clermont PJ, Kim JW, Machesky LM, Rhee SG, Pollard TD. Regulation of phospholipase γ 1 by profilin and tyrosine phosphorylation. **Science** 251:1231-1233, 1991.

30. Goldschmidt-Clermont PJ, Machesky LM, Doberstein SK, Pollard TD. Mechanism of the interaction of human platelet profilin with actin. **J Cell Biol** 113:1081-1089, 1991.
31. Goldschmidt-Clermont PJ and Janmey PA. Profilin: a weak CAP for actin and RAS. **Cell** 66:419-421, 1991.
32. Goldschmidt-Clermont PJ, Furman MI, Wachsstock D, Safer D, Nachmias VT, Pollard TD. The control of actin nucleotide exchange by thymosin β 4 and profilin. A potential regulatory mechanism for actin polymerization in cells. **Mol Biol Cell** 3:1015-1024, 1992.
33. Goldschmidt-Clermont PJ, Mendelsohn ME, Gibbs JB. Rac and Rho in control. **Current Biol** 2:669-671, 1992.
34. Furman MI, Gardner TM, Goldschmidt-Clermont PJ. Mechanism of cytoskeletal reorganization during platelet activation. **Thromb Haemostas** 70:229-232, 1993.
35. Heldman AW, Goldschmidt-Clermont PJ. Cell signalling and motile activity. **Symp Soc Exp Biol**. 1993;47:317-24.
36. Finkel T, Theriot JA, Dise KR, Tomaselli GF, Goldschmidt-Clermont PJ. Dynamic actin structures stabilized by profilin. **Proc Natl Acad USA** 91:1510-1514, 1994.
37. Theriot JA, Rosenblatt J, Portnoy DA, Goldschmidt-Clermont PJ, Mitchison TJ. Involvement of profilin in the actin-based motility of *L. monocytogenes* in cells and cell-free extracts. **Cell** 76:505-517, 1994.
38. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence activated flow cytometry. **J Lab Clin Med** 123:728-740, 1994.
39. Gips SJ, Kandzari DE, Goldschmidt-Clermont PJ. Growth factor receptors, phospholipases, phospholipid kinases and actin reorganization. **Sem Cell Biol** 5:201-208, 1994.
40. Sohn RH, and Goldschmidt-Clermont PJ. Profilin: at the crossroads of signal transduction and the actin cytoskeleton. **Bio Essays** 16:465-472, 1994.
41. Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont PJ. Platelet tyrosine kinase and fibrinogen receptor activation. **Circ Res** 75:172-180, 1994.
42. Kamp TJ, Goldschmidt-Clermont PJ, Brinker JA, Resar JR. Myocardial infarction, aortic dissection, and thrombolytic therapy. **Am Heart J** 128:1234-1237, 1994.
43. Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P. Hemostatic effects of stress hormone infusion. **Anesthesiology** 81:1116-1126, 1994.
44. Addo JB, Bray PF, Faraday N, Grigoryev D, Goldschmidt-Clermont PJ. Surface recruitment but not activation of integrin α IIb β 3 (GPIIb-IIIa) requires a functional actin cytoskeleton. **Arteriosc Thromb Vascul Biol** 15:1466-1473, 1995.
45. Sohn RH, Chen J, Koblan KS, Bray PF, Goldschmidt-Clermont PJ. Localization of a Binding Site for Phosphatidylinositol 4,5-Bisphosphate on Human Profilin. **J Biol Chem** 270:21114-21120, 1995.
46. Weiss EJ, Goldschmidt-Clermont PJ, Grigoryev D, Jin Y, Kickler TS, Bray PF. A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1^{A1} from P1^{A2}. **Tissue Antigens** 46:374-381, 1995.

47. Heldman AW, Tucker RW, Crawford LE, Kandzari DE, Fearon ER, Koblan KS, Goldschmidt-Clermont PJ. EJ-Ras inhibits Phospholipase C γ 1, but not actin polymerization induced by platelet-derived growth factor (PDGF)-BB via phosphatidylinositol-3 kinase. **Circ Res** 78:312-321, 1996.
48. Melillo G, Lima JAC, Judd RM, Goldschmidt-Clermont PJ, Silverman HS. Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during post-infarct left ventricular remodeling. **Circulation** 93: 1447-1458, 1996.
49. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. **New Engl J Med** 334:1090-1094, 1996.
50. Goldschmidt-Clermont PJ, Shear WS, Swartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. **Lancet** 347: 1833, 1996.
51. Schulman SP, Goldschmidt-Clermont PJ, Topol, EJ. The effects of Integrelin, a platelet glycoprotein lib-IIIa receptor antagonist, in unstable angina: a randomized multicenter placebo-controlled trial. **Circulation** 94: 2083-2089, 1996.
52. Crawford LE, Milliken EE, Zweier JL, Becker L, Johnson T, Eissa NT, Crystal RG, Goldschmidt-Clermont PJ. Superoxide-mediated Actin Response in Post-Hypoxic Endothelial Cells. **J Biol Chem** 271: 26863-26867, 1996.
53. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, Chandra NC, Grigoryev D, Dise KR, Sagar M, Fox RJ, Coleman LD, Richardson C, Dorsey F, du Mee C, Kitt MM, Baughman KL, Gerstenblith G. Refining the treatment of women with unstable angina—a randomized, double blind, comparative safety and efficacy of Integrelin versus aspirin in the management of unstable angina. **Clin Cardiol** 19: 869-874, 1996.
54. Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, Finkel T. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. **Biochem J** 318: 379-382, 1996.
55. Sulciner DJ, Irani K, Yu Z-X, Ferrans VJ, Goldschmidt-Clermont P, Finkel T. Rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-KappaB activation. **Molec Cell Biol** 16: 7115-7121, 1996.
56. Schechter AD, Goldschmidt-Clermont PJ, McKee G, et al. Influence of gender, race, and education on patient preferences and receipt of cardiac catheterization among coronary care unit patients. **Am J Cardiol**, 78: 996-1001, 1996.
57. Fleischer KJ, Goldschmidt-Clermont PJ, Fonger JD, Hutchins GM, Baumgartner WA. One-month histologic response of transmyocardial laser channels with molecular intervention. **Ann Thorac Surg** 62: 1051-1058, 1996.
58. Moldovan NI, Milliken EE, Irani K, Chen J, Sohn RH, Finkel T, Goldschmidt-Clermont PJ. Regulation of endothelial cell adhesion by profilin. **Curr Biol** 7:24-30, 1997.
59. Irani K, Xia Y, Zweier JL, Sollott S, Der C, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. **Science** 275:1649-1652, 1997.
60. Faraday N, and Goldschmidt-Clermont PJ. Gender Differences in Platelet GPIIb-IIIa Activation. **Thromb Haemostas** 77(4):748-754, 1997.
- 61.

62. Alvarez RJ, Gips SJ, Moldovan N, Wilhide CC, Milliken EE, Hoang AT, Hruban RH, Silverman HS, Dang CV, Goldschmidt-Clermont PJ. 17beta-estradiol inhibits apoptosis of endothelial cells. **Biochem Biophys Res Comm** 237:372-381, 1997.
63. Motevalli M, Goldschmidt-Clermont PJ, Virgil D, Kwiterovich PO. Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoprotein subjects. **J Biol Chem** 272:24703-24709, 1997.
64. Bray PF, Weiss EJ, Tayback M, Goldschmidt-Clermont PJ. PLA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease. **Lancet** 349:1100-1101, 1997.
65. Takahashi A, Goldschmidt-Clermont PJ, Alnemri ES, Fernandes-Alnemri T, Yoshizawa-Kumagaya K, Nakajima K, Sasada M, Poirier GG, Earnshaw WC. Inhibition of ICE-related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. **Exp Cell Res** 231:123-131, 1997.
66. Jones SA, Goldschmidt-Clermont PJ, Grigoryev D, Aversano T. Effect of stenosis shape on thrombus formation in an in vitro blood flow model. **American Society of Mechanical Engineers, Bioengineering Division BED**, 35, 279-280.
67. Moore KA, Sethi R, Doanes AM, Johnson TM, Pracyk JB, Kirby M, Irani K, Goldschmidt-Clermont PJ, Finkel T. Rac1 is required for cell proliferation and G2/M progression. **Biochem J** 326:17-20, 1997.
68. Irani K and Goldschmidt-Clermont PJ. Ras, Superoxide and Signal Transduction. **Biochem Pharm** 55(9):1339-1346, 1998.
69. Cooke GE, Bray PF, Hamlington J, Pham Y, Goldschmidt-Clermont PJ. Pl^{A2} polymorphism and efficacy of aspirin. **Lancet** 351:1253, 1998.
70. Kim K-S, Takeda K, Sethi R, Pracyk JB, Tanaka K, Zhou YF, Yu Z-X, Ferrans VJ, Bruder JT, Kovetski I, Irani K, Goldschmidt-Clermont P, Finkel T: Protection from Reoxygenation Injury by Inhibition of rac1. **J Clin Invest** 101(9):1821-1826, 1998.
71. Wagner KR; Giles WH; Johnson CJ; Ou CY; Bray PF; Goldschmidt-Clermont PJ; Croft JB; Brown VK; Stern BJ; Feeser BR; Buchholz DW; Earley CJ; Macko RF; McCarter RJ; Sloan MA; Stolley PD; Wityk RJ; Wozniak MA; Price TR; Kittner SJ. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: The Stroke Prevention in Young Women Study. **Stroke** 29:581-585, 1998.
72. Kelly SA; Goldschmidt-Clermont PJ; Milliken EE; Arai T; Smith EH; Bulkley GB. Protein tyrosine phosphorylation mediates TNF-induced endothelial-neutrophil adhesion in vitro. **Am J Physiol** 274:H513-519, 1998.
73. Markovitz JH, Kulkarni K, Goldschmidt-Clermont P, Kiefe CL, Rustagi P, Sekar P, Nanda N: Increased platelet activation and fibrinogen in Asian Indians: Potential implications for coronary risk. **Eur Heart J** 19:720-726, 1998.
74. Arai T, Kelly SA, Brengman ML, Takano M, Smith EH, Goldschmidt-Clermont PJ, Bulkley GB. Ambient but not incremental oxidant generation effects intracellular adhesion molecule 1 induction by tumour necrosis factor in endothelium. **Biochem J** 331:853-861, 1998.
75. Irani K, Pham Y, Coleman LD, Roos C, Cooke GE, Miodovnik A, Karim N, Wilhide CC, Bray PF, Goldschmidt-Clermont PJ. Priming of Platelet $\alpha_{IIb}\beta_3$ by Oxidants is Associated with Tyrosine Phosphorylation of β_3 . **Arterioscl Thrombo Vasc Biol** 18:1698-1706, 1998.
76. Moldovan NI, Qian Z, Chen Y, Dong C, Ying A, Hruban RH, Flavahan NA, Baldwin III WM, Sanfilippo F, Goldschmidt-Clermont PJ. Fas-mediated apoptosis in accelerated graft arteriosclerosis. **Angiogenesis** 2(3):245-254, 1998.

77. Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, Rovira II, Blazina DR, Lee L, Bruder JT, Kovessi I, Goldschmidt-Clermont PJ, Irani K, Finkel T. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. **J Clin Invest** 102:929-37, 1998.
78. Doanes AM, Irani K, Goldschmidt-Clermont PJ, Finkel T. A requirement for rac1 in the PDGF-stimulated migration of fibroblasts and vascular smooth cells. **Biochem Mol Biol Int** 45(2): 279-287, 1998.
79. Goldschmidt-Clermont PJ, and Moldovan L. Stress, superoxide and signal transduction. **Gene Expr** 7: 255-260, 1999.
80. Goldschmidt-Clermont PJ, Roos C, Cooke GE. P1A2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. **J Thrombosis and Thrombolysis** 8(2): 89-103, 1999.
81. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman A, Sussman MS, Ouyang P, Milliken EE, Issa PJP. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. **Cardiovasc Res** 43(4):985-991, 1999.
82. Arai M, Masui Y, Goldschmidt-Clermont P, DiPaula A, Siu C, Kondo T, Becker LC. P-selectin inhibition prevents early neutrophil activation but provides only modest protection against myocardial injury in dogs with ischemia and 48 hours reperfusion. **J Am Coll Cardiol** 34(1): 280-8, 1999.
83. Moldovan L, Irani K, Moldovan, NI, Finkel T, Goldschmidt-Clermont PJ. The actin cytoskeleton reorganization induced by rac1 requires the production of superoxide. **Antioxidants and Redox Signaling** 1(1): 29-43, 1999.
84. Yeh LH, Park YJ, Hansalia RJ, Ahmed IS, Deshpande SS, Goldschmidt-Clermont PJ, Irani K, Alevriadou BR. Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. **Am J Physiol** 276(4Pt1): C838-C847, 1999.
85. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, Cooke GE, Shear WS, Weiss EJ, Kral BG, Moy TF, Yook RM, Blumenthal RS, Becker DM, Becker L, Bray PF. Higher prevalence of GPIIIa P1A2 polymorphism in siblings of patients with premature coronary heart disease. **Arch Path Lab Med** 123(12): 1223-1229, 1999.
86. Kandzari DE, Goldschmidt-Clermont PJ. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. **JAMA** 281(5): 415, 1999.
87. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa P1^A polymorphisms display different sensitivities to agonists. **Circulation** 101:1013-1018, 2000.
88. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JPJ, Michler RE, Caligiuri M, Plass, Goldschmidt-Clermont PJ. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. **Cardiovasc Res** 46(1): 172-179, 2000.
89. Dong C, Li Z, Alvarez R, Feng ZH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF β activity. **Mol Cell** 6(1): 27-34, 2000.
90. Qiu P, Moeschberger ML, Cooke GE, Goldschmidt-Clermont PJ: Sample size to test for interaction between a specific exposure and a second risk factor in a pair-matched case-control study. **Stat Med** 10(7): 923-935, 2000.

91. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The P1A2 polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. **J Clin Invest** 105(6): 793-802, 2000.
92. Wang JHC, Goldschmidt-Clermont P, Moldovan N, Yin FCP: Leukotrienes and Tyrosine Phosphorylation Mediate Stretching-Induced Actin Cytoskeletal Remodeling in Endothelial Cells. **Cell Motility & Cytoskeleton** 46:137-145, 2000.
93. Ozaki M, Deshpande SS, Angkeow P, Bellan J, Lowenstein CJ, Cinauer MC, Goldschmidt-Clermont PJ, Irani K: Inhibition of the rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. **FASEB J** 14(2): 418-429, 2000.
94. Moldovan L, Moldovan NI, Sohn TH, Parikh SA, Goldschmidt-Clermont PJ: Redox changes of cultured endothelial cells and actin dynamics. **Circ Res** 86(5): 549-557, 2000.
95. Dong C and Goldschmidt-Clermont PJ: Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis (editorial). **Circ Res** 86:827-828, 2000.
96. Seshiah PN and Goldschmidt-Clermont PJ: Detection of the threatening atherosclerotic plaque: Technological advancement and opportunities (editorial). **Am Heart J**, 2000.
97. Hassanain H, Sharma YK, Moldovan L, Khramtsov V, Berliner LJ, Duvick JP, Goldschmidt-Clermont PJ. Plant rac proteins induce superoxide in mammalian cells. **Biochem Biophys Res Commun** 272(3):783-788, 2000.
98. Goldschmidt-Clermont, PJ, Cooke GE, Eaton GM, Binkley PF: P1^{A2}, a variant of GPIIb implicated in coronary thromboembolic complications. **J Am Coll Cardio** 36(1): 90-93, 2000.
99. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Start R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J: Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. **J Clin Invest** 106(4): 483-491, 2000.
100. Wang JH, Goldschmidt-Clermont P, Yin FC. Contractility affects stress fiber remodeling and reorientation of endothelial cells subjected to cyclic mechanical stretching. **Ann Biomed Eng** 28(10), 1165-1171, 2000.
101. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. **Circ Res** 87(5): 378-384, 2000.
102. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ. The P1A polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. **Arch Pathol Lab Med** 125(1): 112-115, 2001.
103. Dong C, Nevins J, Goldschmidt-Clermont PJ. ABCA1 single nucleotide polymorphisms. Snipping at the pathogenesis of atherosclerosis. **Circ Res** 88(9): 855-7, 2001.
104. Mikkelsen J, Perola M, Penttila A, Goldschmidt-Clermont PJ, Karhunen PJ. The GPIIb (beta3 integrin) P1A polymorphism in the early development of coronary atherosclerosis. **Atherosclerosis** 154(3): 721-727, 2001.
105. Goldschmidt-Clermont PJ, Kandzari DE, Khouri S, Ferrari M. Nanotechnology needs for cardiovascular sciences. **Biomed Microdevices** 3:2, 83-88, 2001.
106. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E. The platelet P1(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. **Am J Cardiol** 88: 347-352, 2001.

107. Kandzari DE, Goldschmidt-Clermont PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. **J Am Coll Cardiol** 38: 1028-1032, 2001.
108. Kovacic HN, Irani, K, Goldschmidt-Clermont PJ. Redox regulation of human RAC1 stability by the proteasome in human aortic endothelial cells. **J Biol Chem** 276: 45856-45861, 2001.
109. Wang J H-C, Goldschmidt-Clermont P, Wille J, Yin F C-P. Specificity of endothelial cell reorientation in response to cyclic mechanical stretching. **J Biomechanics** 34: 1563-1572, 2001.
110. de Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupe E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of new hybrid procedure compared with "on-pump" double bypass grafting. **Am Heart J** 142(2): 563-570, 2001.
111. Nowicki PT, Flavahan S, Hassanain H, Mitra S, Holland S, Goldschmidt-Clermont PJ, Flavahan NA. Redox signaling of the arteriolar myogenic response. **Circ Res** 89(2): 114-116, 2001.
112. Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, Goldschmidt-Clermont PJ. Redox regulation of vascular smooth muscle cell differentiation. **Circ Res** 89(1): 39-46, 2001.
113. Dong C, Goldschmidt-Clermont PJ. Ras activation of NF-kappa B and superoxide. **Methods Enzymol** 333: 88-96, 2001.
114. Dong C, Zhu S, Alvarez RJ, Goldschmidt-Clermont PJ. Angiotensin II induces PAI-1 expression through MAP kinase-dependent, but TGF beta and PI3 kinase-independent pathway. **J Heart Lung Transplant** 20(2): 226-227, 2001.
115. Dong C, Zhu S, Yoon W, Wang T, Alvarez RJ, Goldschmidt-Clermont PJ. Upregulation of PAI-1 is mediated through TGF beta/SMAD pathway in transplant arteriopathy. **J Heart Lung Transplantation** 20(2): 219, 2001.
116. Ozaki M, Deshpande S, Angkeow P, Bellan J, Lowenstein CJ, Dinauer MC, Goldschmidt-Clermont P, Suzuki S, Irani K. Targeted inhibition of the small GTPase protects against ischemia/reperfusion liver injury in mice. **Transplant Proc.** 2001 Feb-Mar;33(1-2):863-4.
117. Seshiah PN, Kereiakes DJ, Vasudevan SS, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death – Role of macrophage colony-stimulating factor and cell contact. **Circulation** 105: 174-180, 2002.
118. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ. Deficient Smad7 expression: A putative molecular defect in scleroderma. **Proc. Natl Acad. Science** 99: 3908-3913, 2002.
119. Lopes N, Vasudevan SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: Insights at the genomic level. **Prog in Cardiovasc Dis** 44: 323-338, 2002.
120. Taylor DA, Hruban R, Rodriguez ER, Goldschmidt-Clermont PJ. Cardiac chimerism as a mechanism for self-repair: Does it happen and if so to what degree? (invited editorial) **Circulation** 106: 2-4, 2002.
121. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: Abnormalities in vascular and cardiac function and structure. **Circulation** 106: 1154-1158, 2002.
122. Wang T, Dong C, Stevenson SC, Herderich, EE, Marshall-Neff J, Vasudevan SS, Moldovan NI, Michler RE, Movva NR, Goldschmidt-Clermont PJ. Overexpression of *Soluble Fas* Attenuates Transplant Arteriosclerosis in Rat Aortic Allografts. **Circulation** 106: 1536-1542, 2002.

123. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. **J Nutr** 132: 2406S-2409S, 2002.
124. Goldschmidt-Clermont PJ. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. **J Invasive Cardiology**, 14 (Suppl E): 1E-10E, 2002.
125. Goldschmidt-Clermont PJ, Kandzari DE, Sketch MH, Phillips HR. Inflammation, platelets and glycoprotein lib/IIIa inhibitors. **J Invasive Cardiology**, 14 (Suppl E): 18E-25E, 2002.
126. Mayes CE, Kandzari DE, Goldschmidt-Clermont PJ, Phillips HR. The complementary use of glycoprotein lib/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. **J Invasive Cardiology**, 14 (Suppl E): 36E-46E, 2002.
127. Lopes NH, Vasudevan SS, Gregg D, Selvakumar B, Pagano PJ, Kovacic H,, Goldschmidt-Clermont PJ. Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. **Circ Res** 91(9): 798-805, 2002.
128. Dong C, Goldschmidt-Clermont PJ. E2F1: A magic bullet for atherosclerosis? **Circulation** 106: 2640-2641, 2002.
129. Kandzari DE, Goldschmidt-Clermont PJ. Making positive out of negative trials. **Am Heart J**, 143: 950-951, 2002.
130. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H. Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. **Molecular and Cellular Biology**, 23: 5401-5408, 2003.
131. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Phippen AM, Annex BH, Dong C, Taylor DA. Aging, vascular progenitor cell exhaustion and atherosclerosis. **Circulation**, 108: 457-463, 2003.
132. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. **Am J Physiol Cell Physiol** 285: C723-C734, 2003.
133. Vasudevan SS, Lopes N, Seshiah PN, Wang T, Marsh CB, Kereiakes DJ, Dong C, Goldschmidt-Clermont PJ. Mac-1 and Fas activities are concurrently required for execution of smooth muscle cell death by M-CSF-stimulated macrophages. **Cardiovasc Res** 59: 723-733, 2003.
134. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. **J of Am Med Women's Assoc** 58: 272-277, 2003.
135. Goldschmidt-Clermont PJ and Peterson ED. On the memory of a chronic illness. **Sci Aging Knowl Environ (SAGE KE)** (45), re8, 2003.
136. Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. **Am Heart J**, 146:S5-12, 2003.
137. French JK, Van de Water NS, Sutton TM, Lund M, Gao W, McDowell J, Liu-Stratton Y, Pohorence J, Szymanski D, Goldschmidt-Clermont P, White HD, Browett PJ, Cooke G. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. **Am Heart J**, 145(1): 118,124, 2003.
138. Gregg D, Goldschmidt-Clermont PJ. Platelets and cardiovascular disease. **Circulation**, 108:e88-e90, 2003.

139. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet P1A polymorphism of glycoprotein IIIa and risk of coronary heart disease. **Stat Med**, 22(10): 1741-1760, 2003.
140. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray PF. Shear stress augments the enhanced phenotype of cells expressing the Pro33 isoform of integrin beta3. **FEBS Letter**, 540(1-3): 41-46, 2003.
141. Williams RS and Goldschmidt-Clermont PJ. The genetics of cardiovascular disease: from genotype to phenotype. **Dialogues in Cardiovascular Medicine**, 9(1): 3-19, 2004.
142. Zhu S, Goldschmidt-Clermont PJ, Dong C. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. **Circ Res** 94(5):617-625, 2004.
143. Goldschmidt-Clermont PJ, Lam G, Dong C. Progenitor cell dysfunction: A key trigger for atherosclerotic inflammation. **Drug Discovery Today: Disease Mechanisms**, 1:53-58, 2004.
144. Califf RM, Ryan T, Douglas P, Goldschmidt-Clermont PJ. A time of accelerated change in academic cardiovascular medicine. **J Am Coll Cardiol**, 44:1957-1965, 2004.
145. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Schulteis R, Milano CA, Rigat F, Pittman J, Nevins JR, West M, Goldschmidt-Clermont PJ. Gene expression phenotypes of atherosclerosis. **Arterioscler Thromb Vasc Biol**, 24 (10): 1922-1927, 2004.
146. Hassanain HH, Irshaid F, Wisel S, Sheridan J, Michler RE, Goldschmidt-Clermont PJ. Smooth muscle cell expression of a constitutive active form of human Rac 1 accelerates cutaneous wound repair. **Surgery**, 137:92-101, 2005.
147. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL, Rokovich J, Johnstone B, Rebar EJ, Spratt SK, Case CC, Kontos CD, Annex BH. Engineered zinc finger- activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hind-limb ischemia. **Circulation** 110(16): 2467-2475, 2004.
148. Dong C, Crawford LE, Goldschmidt-Clermont PJ. Endothelial progenitor obsolescence and atherosclerotic inflammation. **J Am Coll Cardiol**, 45:1458-1460, 2005.
149. Ajjola OA, Goldschmidt-Clermont PJ, Satterwhite LL. CD40 ligand: not bad to the bone (marrow) after all. **Arterioscler Thromb Vasc Biol**, 25(6): 1088-1090, 2005.
150. Karra R, Vemullapalli S, Dong C, Herderick EE, Nevins JR, West M, Goldschmidt-Clermont PJ, Seo D. Molecular evidence for arterial repair in atherosclerosis. **Proc Natl Acad Sci**. 102 (46):16789-94, Nov, 2005.
151. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: Recent discoveries and novel hypotheses. **Circulation**. 112(21):3348-53, Nov, 2005.
152. Kong DF, Goldschmidt-Clermont PJ. Tiny solutions for giant cardiac problems. **Trends in Cardiovasc Med**. 15(6):207-11, Aug, 2005.
153. Zhu S, Goldschmidt-Clermont PJ, Dong C. Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. **Circulation**. 112 (9): 1353-61, Aug, 2005.
154. Liu X, Zhu S, Wang T, Hummers L, Wigley F, Goldschmidt-Clermont PJ, Dong C. Paclitaxel modulates TGF β Signaling in scleroderma skin grafts in immunodeficient mice. **Plos Med**. 2(12): e354, Dec, 2005.

155. Wang T, Davis BH, Herderick EH, Whitesides JF, Yue B, Taylor DA, Goldschmidt-Clermont PJ, Transfer of bone marrow cells suppresses atherosclerotic inflammation in aged ApoE-deficient mice. *Circulation*. In press, 2005.
156. Goldschmidt-Clermont PJ, Diehl AM. Arterial homeostasis, inflammation, and erythropoietic growth factors. *Rev Cardiovasc Med*. 2005;6 Suppl 3:S22-6.
157. Kravchenko J, Goldschmidt-Clermont PJ, Powell T, Stallard E, Akushevich I, Cuffe MS, Manton KG. Endothelial progenitor cell therapy for atherosclerosis: The philosopher's stone for an aging population? *Sci Aging Knowledge Environ*, 25:18, 2005
158. Stenger JE, Xu H, Haynes C, Hauser ER, Pericak-Vance M, Goldschmidt-Clermont PJ, Vance JM. Statistical viewer: a tool to upload and integrate linkage and association data as plots displayed within the Ensembl genome browser. *BMC Bioinformatics* 12(6), 95, 2005.
159. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. *J Am Coll Cardiol*. 2006 Feb 7;47(3):541-6. Epub 2006 Jan 18.
160. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolattukudy PE. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. *J Mol Cell Cardiol*. 2006 Jun;40(6):810-20. Epub 2006 May 5.
161. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. *Cardiovasc Res*. 2006 Jul 15;71(2):236-46. Epub 2006 May 9.
162. Boudoulas KD, Montague KR, Goldschmidt-Clermont PJ, Cooke GE. Estradiol increases platelet aggregation in PIA1/A1 individuals. *Am Heart J*. 2006 Jul;152(1):136-9.
163. Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. *J Am Coll Cardiol*. 2006 Jul 18;48(2):227-35.
164. Kunz GA, Liang G, Cuculoski F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED. Circulating endothelial progenitor cells predict coronary artery disease severity. *Am Heart J*. 2006 Jul;152(1):190-5.
165. Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, Crosslin DR, Hale AB, Nelson S, Crossman DC, Granger CB, Haines JL, Jones CJ, Vance JM, Goldschmidt-Clermont PJ, Kraus WE, Hauser ER, Gregory SG. GATA2 Is Associated with Familial Early-Onset Coronary Artery Disease.. *PLoS Genet*. 2006 Aug 25;2(8).
166. Montague CR, Hunger MG, Gavrilin MA, Phillips GS, Goldschmidt-Clermont PJ, Marsh, CB. Activation of Estrogen Receptor Alpha Reduces Aortic Smooth Muscle Differentiation. *Circ Res*. 2006 Sep 1;99(5):477-84.
167. Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout SD, Nelson CL, Sinnaeve P, Goldschmidt-Clermont PJ, Granger CB. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. *Am Heart J*. 2006 Sep;152(3):478-85.
168. Kim J, Kim JY, Song KY, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa, JP. Epigenetic changes in estrogen receptor β gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. *Biochim Biophys Acta*. 2006 Oct 12.

169. Cooke G, Goldschmidt-Clermont PJ. The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. **Expert Opin. Drug Saf.** 2006 Nov;5(6):815-26.
170. Choi SS, Sicklick JK, Ma Q, Yang L, Huang J, Qi Y, Chen W, Li YX, Goldschmidt-Clermont PJ, Diehl AM. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. **Hepatology.** 2006 Nov;44(5):1267-77.
171. Zhu S, Liu X, Li Y, Goldschmidt-Clermont PJ, Dong C. Aging in the Atherosclerosis Milieu May Accelerate the Consumption of Bone Marrow Endothelial Progenitor Cells. **Arteriosclerosis, Thrombosis, and Vascular Biology** (published online Nov 9, 2006).
172. Hassanain HH, Gregg D, Marcelo ML, Zweier JL, Souza HP, Selvakumar B, Ma Q, Moustafa-Bayoumi M, Binkley PF, Flavahan NA, Morris M, Dong C, Goldschmidt-Clermont PJ. Hypertension Caused by Transgenic Over-expression of Rac1. **Antioxidants & Redox Signaling** 2007 Jan;9(1):91-100.
173. Seo DM, Goldschmidt-Clermont PJ. Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment. **Expert Rev Mol Diagn.** 2007 Jan;7(1):45-51.
174. Vemulapalli S, Metzler SD, Akabani G, Petry NA, Niehaus NJ, Liu X, Patil NH, Greer KL, Jaszczak RJ, Coleman RE, Dong C, Goldschmidt-Clermont PJ, Chin BB. Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. **Radiology.** 2007 Jan;242(1):198-207.
175. Wang L, Vance J, Pericak-Vance M, Shah S, Hauser ER, Goldschmidt-Clermont PJ, Krauss WE. Peak-wide mapping on chromosome 3q13 identifies the kalirin gene as a novel susceptibility gene for coronary artery disease. **American Journal of Human Genetics.** 2007 Apr;80(4):650-63. Epub 2007 Feb 8.
176. Dong, C. and Goldschmidt-Clermont PJ. Endothelial progenitor cells: A promising therapeutic alternative for cardiovascular disease. **J Interv Cardiol.** 2007 Apr;20(2):93-9.
177. Seo DM, Goldschmidt-Clermont PJ, West M. Of Mice and Men: Sparse Statistical Modeling in Cardiovascular Genomics. **Annals of Applied Statistics.** 2007, Vol. 1, No. 1, 152-178.
178. Tabatabaei N, Stout J, Goldschmidt-Clermont P, Murdoch D. Central Nervous System Infection and Cutaneous Lymphadenitis Due to Mycobacterium kansasii in an Immunocompetent Patient. **Infection.** 2007 Aug;35(4):291-4. Epub 2007 Jul 23.
179. Liao SM, Goldschmidt-Clermont PJ, Sugarman J. Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. **J Med Ethics.** 2007 Nov;33(11):643-6.
180. Moustafa-Bayoumi M, Alhaj MA, El-Sayed O, Wisel S, Chotani MA, Aboelnaga ZA, Hassona MD, Morris M, Nuovo G, Zweier JL, Goldschmidt-Clermont P, Hassanain H. Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1. **J Biol Chem.** 2007 Oct 16.
181. Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, Dong C, Peterson ED. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. **J Am Coll Cardiol.** 2007 Dec 4;50(23):2243-8. Epub 2007 Nov 19.
182. Wang H, Yan B, Satterwhite LL, Ma Q, Goldschmidt-Clermont PJ. Increased activity of phosphatase PP2A in the presence of the PIA2 polymorphism of alphasbeta3. **Biochem Biophys Res Commun.** Volume 367, Issue 1, 29 February 2008, Pages 72-77. Epub 2007 Dec 26.
183. Wang, L, Hauser, B; Shah S; Seo D, Sivashanmugam P, Exum S, Gregory S, Haines J, Crossman D, Haynes C, Kraus W, Freedman N, Pericak-Vance M, Goldschmidt-Clermont PJ, Vance J.

Polymorphisms of the tumor suppressor gene LSAMP are associated with left main coronary artery disease. **Annals of Human Genetics** (accepted).

184. Ajjola OA, Dong C, Herderick EE, Ma Q, Goldschmidt-Clermont PJ, Zhen Y. Voluntary running suppresses atherogenic cytokines and improves longevity in Apolipoprotein-E deficient mice. **Antioxidant and Redox** (submitted).
185. Chen GL, Goldschmidt-Clermont PJ. The Journey in the Treatment of Myocardial Infarction. **Cardiology** (submitted).
186. Ma Q, Cavallin L, Yan B, Zhu S, Duran EM, Wang H, Hale LP, Dong C, Mesri EA, Goldschmidt-Clermont PJ. Activated Rac1, aging and male gender predispose mice to Kaposi's Sarcoma-like tumorigenesis. **PNAS** (in preparation).

V. Professional

Building and Development:

Ciccarone Center for the Prevention of Heart Disease, JHU (raised \$1.5M)

Davis Heart and Lung Research Institute, OSU (raised \$15M)

Ross Heart Hospital, OSU (raised \$10M)

Global Health Initiative, Duke (raised \$6.5M)

Britt Philanthropic Gift, Duke (\$10 million)

Momentum: The Campaign for the University of Miami - Successful \$1.4 billion University campaign, completed January 2008. \$786 million raised for medical school initiatives.

Annual Giving University of Miami- \$120 million cash raised for medical school initiatives in fiscal year 2007

NIH Study Section (past):

Ad Hoc NHLBI

K23/K24 Awards

Experimental Cardiovascular Sciences

Atherosclerosis and Inflammation in the Cardiovascular Sciences

Peer-Reviewed and Funded Research:

Current:

Field: Reactive Oxygen Species, Inflammation, Small GTP-Binding Proteins, and Hypertrophy, Hypertension and Atherosclerosis

Funded:

(1) R0-1: Rac, Superoxide and Antioxidants in Hypertension

NIH#: HL071536

Role on grant: P.I. (15% effort)

Dates: 07.01.02 through 06.30.08 (no-cost extension)

Total Direct Cost: \$1,250,000

(2) R01 AG023073-01A1, Impact of Aging on Stem Repair in Atherosclerosis

Role on grant: P.I. (10% effort)

Dates: 7.1.04 through 6.30.09

Total Direct Cost: \$1,925,000

(3) Ryan White Title I Health and Support Services for Persons Living with HIV/AIDS REP#0307

Miami-Dade County

Role on grant: PI

Dates: 3.01.2007 – 2.29.2008

Past Awards:

P01 HL73042/HG02384, A Comparative Approach to Genomics of Complex Traits
Role on grant: Consultant
Dates: 9.30.02 through 04.01.06

Scleroderma Research Foundation. Systemic Sclerosis: Molecular mechanisms underlying vascular cell abnormalities and intimal lesion formation in scleroderma. Emphasis: TGF- β and Smads
Role on grant: Consultant
Dates 09.01.94 through 04.01.2006

HL36587 The Genetics of Biobehavioral Risk Factors for CVD
Role: Project 1 – Consultant
Core C - Dates: 1.25.04 through 04.01.2006

RR17630-03 Mentored Clinical Research Scholar Program
Role: Mentor
Dates: 9.30.02 through 04.01.2006

HL075752-01 Angiogenesis and Mechanisms of Exercise Training in PAD
Role: Consultant
Dates: 9.30.03 through 04.01.2006

HL073389-02: GENECARD: Gene Identification in Early-Onset CAD
Role: Consultant
Dates: 4.01.03 through 04.01.2006

Field: Organization and regulation of actin cytoskeleton
R0-1 Title GM053236: Profilin I: an essential protein in cells and animals.
NIH#: HD53236. Role on project: P.I. (20%).
Dates: 6.1.96 to 5.31.02 (renewed as HL71536)

Field: Cell signaling in post-ischemic inflammation
SCOR-project title: Tyrosine kinase signaling pathway in post-ischemic inflammation. NIH#: HL52315. Role on project: P.I. (50%).
Dates: 1.15.95 to 12.31.99

American Heart Association Established Investigator Award project title: Tyrosine kinase signaling pathway in post-ischemic inflammation. AHA#:0 95002600. Role on project: P.I.
Dates: 7.1.96 to 6.30.00
R01 – 728865

Field: Endothelial cell dysfunction, growth factors and vasoactive mediators in accelerated graft arteriosclerosis.
Project Title: Endothelial cell dysfunctional apoptosis in AGA.
Funding organism: Sandoz Pharmaceutical. Role on project: P.I. (5%). Dates: 5.1.96 to 4.30.00

NIH-P01 HL5691.

Role on project: PI (20%)

Dates: 04.01.97 to 03.31.01

Field: Integrins, polymorphisms, thrombosis and pharmacogenetics

R0-1 Title: Platelet PLA2: studies on a pro-thrombotic polymorphism.

NIH#: DK57488.

Role on project: Co-Investigator (10%; P.I.: Paul F. Bray).

Dates: 01.01.97 to 12.31.01.

R0-1: Dynamics of Flow-Dependent Arterial Permeability

NIH#: HL50442

Role on grant: Co-Investigator (10% effort, P.I.: M. Friedman)

Dates: 04.0.01 through 03.31.04

Total Direct Cost: \$1,250,000

Doris Duke Clinical Interfaces Award, Progenitor Cell Based
Therapeutic Strategies for Atherosclerosis

Dates: 10.1.03 through 3.31.05

Total Direct Cost: \$80,000

MEDUSA Goldschmidt (PI) 7/1/02 – 6/30/05

Medtronics

Medtronic/Duke Cardiovascular Strategic Alliance

To improve human welfare.

M01: General Clinical Research Center

NIH# RR16587

Role on grant: P.I. (5% effort)

Dates: 08/15/2002- 03/31/2007

Additional Past Grants:

1991-1993

Clinician Scientist Award: P.I. Tyrosine phosphorylation of
phospholipase C and cytoskeleton reorganization

1992-1994

AHA-Grant-In-Aid: P.I. The control of cell shape by receptor
tyrosine kinase.

1992-1995

Syntex Scholars Program Award: P.I. The control
of cell motility by receptor tyrosine kinase

Patents:

1. Rac-Like Genes and Methods of Use (*Jonathan Duvick, Pioneer Hi Bred, patent # WO0015800*)
2. Use of Platelet Polymorphism PI^{A2} to Diagnose Risk of Thrombotic Disease (*patent #5955266, issued 9/21/99*)
3. Microtubule Binding to Smads Regulates TGF-beta Activity
4. Use of Plant Rac Isoforms for Human Applications
5. Gene Therapy (SfasR) (*Novartis, patent # WO0063369*)
6. Fas-Null Pigs for Xenotransplantation
7. Gene Whose Expression has Predictive Value for Atherosclerosis
8. Prevention of Atherosclerosis with Vascular Progenitor Cells
9. Atherosclerotic Phenotype Determinative Genes and Methods for Using the Same (*Nevins, Patent #WO20030913, 11/06/03*)
10. Stem Cell Therapy for the Prevention of Atherosclerosis and Related Ailments
11. Use of EASD Technology for Intervention on Blood Vessels and Other Cardiovascular Structures

12. Use and Detection of Stem Cell Carriers to Deliver Nano- and Micro-Devices to the Vessel Wall
13. Use of the Exo-Arterial Snake Device (CASD) Technique
14. Induction of CD133+/CD34+ Cell Proliferation and Differentiation
15. Discovery of Simple Little Cells
16. Novel Technology to Assess with Unprecedented Accuracy the Impact of Drugs and Small Molecules on Atherosclerosis and Related Complications
17. Molecular Signature for Arterial Repair by Progenitor Cells, Discovery of New Markers and Targets for Cardiovascular Disease
18. Genes providing susceptibility to developing cardiac disease and atherosclerosis (in process)
19. Progenitor Cells and Methods of Using Same (*Goldschmidt, 11/4/2004, patent # 2004078927*)
20. Atherosclerosis (*in process with Chunming Dong, Duke*)
21. Pretreatment of bone marrow derived stem cells to improve reparative capability (*in process with David Seo, UM*)
22. Method of inhibiting atherosclerotic plaque destabilization (*Goldschmidt, 7/4/2003, app# 20030138857*)
23. Atherosclerotic phenotype determinative genes and methods for using the same (*West, 12/4/2003, app # 20030224383*)
24. Tumors that are indistinguishable from Kaposi Sarcoma (with Qi Ma, UM)
25. Methods and compositions for correlating genetic markers with cardiovascular disease (*Jeff Vance, 10/27/05, app # 20060115845; App 11/260842*)
26. Atherosclerotic phenotype determinative genes and methods for using the same (*West, 03/09/06, patent # WO20060260*)
27. LSAMP Gene Associated With Cardiovascular Disease (*with Jeff Vance, app date: 07/08/2007, application number 20070148661; 11/458228*)
28. Methods of determining the risk of developing coronary artery disease (*Hauser, Duke University, patent # WO20070869*)

Mentoring:

1. M.I. Furman, former fellow in cardiology, now Assistant Professor, Cardiology, Dept. of Medicine, U.Mass
2. A.W. Heldman, former fellow in cardiology
Recipient of A.H.A Fellowship Award 1993
Assistant Professor, Cardiology, Johns Hopkins
3. L.E. Crawford, former fellow in cardiology, Assistant Professor, Cardiology Division, Duke University
4. S. Gips, former fellow in Cardiology
5. Wendy Post, former fellow in Cardiology, now an Assistant Professor at Johns Hopkins University
6. Jeffrey Rade, former fellow in Cardiology, now an Assistant Professor at Johns Hopkins University
7. Kaikobab Irani, former fellow in Cardiology, now an Assistant Professor at Johns Hopkins University
8. R. Sohn, former M.S. IV, 4-school program
M.D. graduate from Johns Hopkins, Chief Medicine Resident, Johns Hopkins, now faculty in Cardiology at UCSF
9. D. Kandzari, Sarnoff fellow, now Assistant Professor in Cardiology, Duke University
10. E. Weiss, MS-IV, Recipient of the Paul Erlich Prize, Johns Hopkins University, resident in Medicine at Johns Hopkins University, now faculty in Cardiology at UCSF

11. Glen Cooke, former fellow in Cardiology OSU, now Assistant Professor in Cardiology at OSU
12. Nicandor Moldovan, Research Scientist, Heart and Lung Institute, OSU, now Assistant Professor, Engineering at OSU
13. Leni Moldovan, Research Scientist, Heart and Lung Institute, OSU, now research scientist at OSU
14. Rene Alvarez, Cardiology Fellow at Hopkins, now Cardiology private practice, Reading, PA
15. Chunming Dong, Research Scientist, Heart and Lung Institute, OSU; now research assistant professor at Duke University
16. Hamdy Hassanain, Research Scientist, Heart and Lung Institute, OSU
17. Christine Roos, Fellow, Heart and Lung Institute, OSU
18. Anita Kuo Ying, Sarnoff Fellow/CR Med/Ped program at Duke, now faculty at Baylor
19. Tao Wang, Fellow, Heart and Lung Institute, OSU, now Assistant Research Professor at Univ Penn
20. Dean Boudoulas, Medical Student, OSU, now resident
21. Herve Kovacic, Fellow, Heart and Lung Institute, OSU, now Assistant Professor, University of Marseille
22. Neuza Lopes, Visiting Scholar, Heart and Lung Institute, OSU, now Cardiology faculty Univ de Sao Paulo, Brazil
23. Frederick Rauscher, Sarnoff fellow, Medical Student, DUMC, now Ophthalmology Resident
24. David Gregg, Research Post-Doc Fellow, DUMC, now Cardiology Fellow, UCSF
25. Degen Zhou, Research Associate, DUMC
26. Shoukang Zhu, Research Associate, DUMC
27. Grace Liang, Research Associate, DUMC, now research faculty at Univ Penn
28. Sanjay Vasudevan, research fellow, DUMC, now Medicine resident, Univ of Pittsburgh
29. Bala Selvakumar, Graduate Student, Cell Biology, DUMC, now Research Associate, DUMC
30. Qi Ma, Graduate Student, Cell Biology, DUMC, now Postdoctoral Associate at University of Miami Miller School of Medicine
31. Woohyun Yoon, Graduate Student, Cell Biology, DUMC
32. Huili Wang, Graduate Student, Pathology, DUMC now Research Associate, DUMC
33. Korkut Vata, Graduate Student, Pathology, DUMC
34. David Seo, Clinical and Research Cardiology Fellow, DUMC, now Assistant Professor, DUMC
35. Anil Panigrahi, Research Associate, DUMC, now MD/PhD student at Univ Penn
36. Ravi Karra, Medical Student, DUMC
37. Sreek Vermulapalli, Medical Student, DUMC
38. Arashk Motiei, Medical Student, DUMC
39. Brian Yue, Medicine Resident, DUMC
40. Ryan Schulteis, Medical Student, DUMC, now MD/PhD Student, Univ of WI
41. Olujimi Aijola, Medical Student, DUMC
42. Sarah Evans, Medical Student, DUMC
43. Anuj Malhotra, Medical Student, DUMC
44. Enrikas Vainorius, Research Assoc, DUMC
45. Jason Koontz, Cardiology Fellow, DUMC
46. Gregory Lam, Cardiology Fellow, DUMC
47. Ayesha Sarpong, Medical Student, DUMC
48. Albert Sun, Int Medicine Resident, DUMC
49. Thomas Povsic, Cardiology Fellow, now Assist

- Prof of Med, DUMC
50. Mythreye Karthikeyan, Research Assoc, DUMC
 51. Lisa Satterwhite, Sr Research Scientist, DUMC
 52. Xiachua Song, Research Assoc, DUMC
 53. Xialin Liu, Sr Research Assoc, DUMC

Invited Lectureships:

Speaker, Joint Meeting of the Societies for Cell Biology and for Biochemistry and Molecular Biology, San Francisco, California, 1989

Speaker, Cardiology Division Research Lecture Series, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1990

Lecturer, Seminaire Extraordinaire
Erasme Academic Hospital, Brussels, Belgium, 1990

Speaker, Research Lecture, National Cancer Institute, Bethesda, Maryland, 1990

Finalist, Katz Prize Competition, American Heart Association Meeting, Dallas, Texas, 1990

Lecturer, Interurban Clinical Club Meeting
Johns Hopkins University School of Medicine
Baltimore, Maryland, 1991

Speaker 193rd Annual Meeting of the Medical and Chirurgical Faculty of Maryland, University of Maryland, College Park, Maryland, 1991

Speaker, American Society of Cell Biology Meeting, Boston, MA, 1991

Speaker, Division of Cardiology, University of Cincinnati, Cincinnati, OH, 1992

Speaker, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, 1992

Speaker, Syntex Laboratories, Syntex Scholars Program, Palo Alto, CA, 1992

Speaker, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 1992

Speaker, Department of Medicine, University of Michigan, Ann Arbor, MI, 1992

Speaker, "Actin 1992" Meeting, Albany, NY, 1992

Medical Grand Rounds, Johns Hopkins University, School of Medicine, Baltimore, MD, 1992

Speaker, Gordon Research Conference, Motile & Contractile Systems, Plymouth, NH, 1992

Speaker, 3rd Abercrombie Symposium, Cell Behaviour: Adhesion & Motility, Society for Experimental Biology
British Society for Cell Biology, University of Bath, England, 1992

Speaker, Cold Spring Harbor Meeting on Cytoskeleton and Cell Function Meeting, Cold Spring Harbor, NY, 1993

Lecturer, Nicholson Lecture
Tuft University, Boston, MA, 1993

State of the Art Lecturer, XIVth Congress of the International Society on
Thrombosis and Hemostasis, New York, NY, 1993

Medical Grand Rounds, Johns Hopkins University, School of Medicine,
Baltimore, MD, 1994

Speaker, Experimental Medicine Division, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, 1994

Speaker, Vascular Medicine and Atherosclerosis Unit
Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
1994

Speaker, 43rd Annual Scientific Session
American College of Cardiology, Atlanta, GA, 1994

Speaker, Gordon Research Conference on Hemostasis, Proctor
Academy, Andover, NH, 1994

Speaker, 67th Scientific Sessions AHA
American Heart Association, Dallas, TX, 1994

Medical Grand Rounds, Johns Hopkins University
School of Medicine, Baltimore, MD, 1994

Speaker, Cardiology Grand Rounds, Beth Israel Hospital, Harvard
Medical School, Boston, MA, 1995

Speaker, Vascular Biology Seminar, Beth Israel Hospital, Harvard
Medical School, Boston, MA, 1995

Speaker, Cardiology Grand Rounds, University of Massachusetts,
Worcester, MA, 1995

Speaker, Basic Seminar Physiology Department, University of
Southwestern Texas, Dallas, TX, 1995

Speaker, Johns Hopkins Medical and Surgical Association Biennial
Meeting, Baltimore, MD, 1995

Lecturer and Session Chairman
Jacques Monod Conferences 1995 Morphogenic Functions of Actin-
Associated Proteins, Aussois, France, 1995

Lecturer and Chairperson
International Meeting on Cytoskeleton and Cancer
Embiez, France, 1995

Speaker, "Thrombosis in Myocardial Infarction Trialist Meeting," Brigham
and Women's Hospital, Harvard Medical School, Boston, MA, 1995

Speaker, 4th Yale Cell Biology Symposium Peripheral "Cytoskeleton
Dynamics in Health and Disease"
Yale University, School of Medicine, New Haven, CT, 1996

Speaker, "Coronary Heart Disease and Atherosclerosis

a Preventable Condition," St. Mary's Medical Center
& Good Samaritan Medical Center, Intracoastal Health Systems, Inc.,
West Palm Beach, FL, 1996

Speaker, FASEB-Meeting, Physiology and Pathology of the Splanchnic
Circulation, Copper Mountain, CO, 1996

Speaker, Keystone Symposia on Molecular and Cellular Biology,
Keystone, CO, 1996

Speaker, "Superoxide: Unexpected Mediator of Cell Signaling", The
Cleveland Clinic Foundation, Cleveland, OH, 1997

Speaker, Division of Cardiology Spring Conference
"From Genes to Myocardial Infarction: Frontiers of Cardiovascular
Science and Medicine in the 21st Century"
The Ohio State University, Columbus, OH, 1997

Grand Rounds, Department of Medicine
"New Genetic Factors in Ischemic Heart Disease"
Columbia Presbyterian Medical Center, New York, NY, 1997

Speaker, XIX Congress of the European Society of Cardiology, "Genes
and Coronary Thrombosis"
Stockholm, Sweden, 1997

Speaker, 28th Annual Postgraduate Medical Seminar
"Risk Factors in Coronary Thrombosis"
Portsmouth, OH, 1997

Speaker, 11th Annual Cardiology Symposium, "The Advances in
Molecular Cardiology: Hope for the Future or Simply Hype?" Columbus,
OH, 1998

Speaker, 21st Annual Conference on Shock
"Post Translational Signaling", San Antonio, TX, 1998

Speaker, Grand Rounds, Department of Internal Medicine
"Can Genomic Therapeutics be Applied in Managing Unstable Coronary
Syndrome?"
The Ohio State University, Columbus, OH, 1998

Speaker, XX Congress of the European Society of Cardiology
"Platelet Glycoproteins," Vienna, Austria, 1998

Speaker, Cleveland Clinic Foundation, Summit on Cholesterol and
Coronary Risk, "Prospective on Genetics and Cardiovascular Disease,
Cleveland, OH, September 3, 1998

Speaker, Symposium on Atrial Fibrillation and Antiplatelet Therapy: 1998
and Beyond, Cleveland, OH, September 19, 1998

Speaker, Grand Rounds, University of Pittsburgh, "Acute Coronary
Syndromes and PIA2", Pittsburgh, PA, October 8, 1998

Keynote Speaker, Fall 1998 AMSECT Region V Meeting, Perfusion: Then
and Now, Columbus, OH, October 10, 1998

Speaker, Grand Rounds, Medical College of Ohio, Division of Cardiology, "Antiplatelet Therapy: Utilizing Genetic Analysis", Toledo, OH, October 15, 1998

Speaker, Grand Rounds, Medical College of Ohio, Department of Pharmacology, "The Role of Oxidants in Cell Motility and Survival," February 17, 1999

Speaker, Grand Rounds, University of Minnesota, "Genetic Traits and Pharmacogenomics for Heart Attacks," February 18, 1999

Speaker, Grand Rounds, Wright State University, "Genetic Traits and Pharmacogenomics for Heart Attacks," February 25, 1999

Speaker, Grand Rounds, Genetic Traits in Pharmacogenomics for Heart Attacks," Kettering Memorial Hospital, Dayton, OH, 1999

Speaker, 8th Annual Seminar on Molecular Pathology, "Platelet Glycoprotein IIIa Polymorphism and Risk for Coronary Thrombosis", William Beaumont Hospital, Royal Oak, MI, March 26-27, 1999

Speaker, Grand Rounds, "Genetic Traits and Pharmacogenomics for Heart Attacks," Boston University, Boston, MA, April 5-6, 1999

Speaker, Grand Rounds, "Genetic Traits and Pharmacogenomics for Heart Attacks," University of Pennsylvania, Philadelphia, PA, April 8, 1999

Speaker, "Oxidants in mitogenic signaling and cell motility" American Physiological Society Annual Meeting, Washington, DC, April 19-20, 1999

Speaker, Grand Rounds, "New Advances in Antiplatelet Therapy", Case Western Reserve University, Cleveland, OH, April 28, 1999

Speaker, Grand Rounds, Genetic and Pharmacogenetic Aspects of Unstable Ischemic Coronary Events", University Hospitals of Cleveland, Cleveland, OH, April 29, 1999

Speaker, Grand Rounds, "Molecular Basis of Atherosclerosis," Fawcett Center, The Ohio State University, Department of Pathology, May 6, 1999

Speaker, Grand Rounds, "The Role of Glycoprotein IIB-IIIa Platelet Inhibitors," Vanderbilt University, Nashville, TN, June 2, 1999

Speaker, Symposium, "Molecular Medicine from Gene to Therapy", Cleveland Clinic Foundation, Cleveland OH, June 4, 1999

Speaker, Grand Rounds, "New Advances in Antiplatelet Therapy", Wright Patterson Air Force Base, Dayton OH, July 8, 1999

Speaker, Grand Rounds, "Current Management of Acute Coronary Syndromes", Queen's Medical Center, Honolulu HI, September 1, 1999

Speaker, First Annual Kyrenia Cardiovascular Center Symposium, New York Hospital Medical Center, Queens NY, October 19, 1999

Speaker, Grand Rounds, "Platelet Inhibition in Acute Coronary Syndromes: From Bench to Bedside", Mt. Carmel Medical Center, Columbus OH, October 26, 1999

Speaker, Grand Rounds, "Pathogenesis and Genetics of Atherosclerosis", The Ohio State University Medical Center, Columbus OH, November 4, 1999

Speaker, Grand Rounds, "New Advances in Antiplatelet Therapy", University of Cincinnati, Cincinnati OH, December 7, 1999

Speaker, Grand Rounds, "Gene Therapy and Heart Disease", Case Western Reserve, Cleveland OH, December 16, 1999

Speaker, Grand Rounds, "Genetics and Pharmacogenetics of Ischemic Heart Disease", Duke University Medical Center, Durham NC, January 31, 2000

Speaker, 9th Annual Seminar on Molecular Pathology, William Beaumont Hospital, Beaumont MI, April 14, 2000

Speaker, Intervention 2000-Critical Review of Interventional Technology and Interventional Catheterization Skills, "New Advances in Molecular-Based Imaging," Atlanta, GA, September 9, 2000

Speaker, Biomedical Engineering Seminar Series, "Nano-Cardiology: Are we there Yet?" Duke University Medical Center, Durham, NC, September 15, 2000

Speaker, Grand Rounds, "Pharmacogenomics of Coronary Thrombosis," University of Michigan, Ann Arbor, MI, September 19, 2000

Speaker, Treatment Strategies for Acute Coronary Syndromes, "Overview of IIB/IIIA Field-Where are we Going?" Pinehurst, NC, September 23, 2000

Speaker, BioMEMS & Biomedical Nanotechnology World 2000, "Unmet Needs and Potential Applications: Cardiology," Columbus, OH, September 26, 2000

Speaker, "New Treatments with Antiplatelet Agents," Charlotte, NC, September 30, 2000

Speaker, Current Concepts in the Diagnosis and Treatment of Adult Heart Disease, "Human Genotyping", Pensacola, FL, October 6, 2000

Speaker, Graylyn Conference on Women's Health, Effects of Estrogen on Thrombosis and Inflammation, "Platelet Function", Winston-Salem, NC, October 12, 2000

Speaker, Ohio State Heart and Lung Institute, Cardiology Update 2000 Symposium, "Thrombosis and Inflammation: Inseparable Processes in Acute Coronary Syndromes, Columbus, OH, October 13, 2000

Speaker, Transcatheter Cardiovascular Therapeutics (TCT) Symposium, "Genetic Mapping to Direct Customized Therapies", Washington, DC, October 18, 2000

Speaker, Emerging Trends in the Management and Treatment of Atherosclerosis, "New Advances in Antiplatelet Therapy", Chicago, IL, October 21, 2000 and Hot Springs, VA, October 27, 2000

Speaker, Platelet Management and Beyond in Acute Coronary Syndromes: A Multifactorial Approach, "Beyond the Platelets: Plaque Stabilization-Survival Mechanisms of Abciximab, New Orleans, LA, November 11, 2000

Speaker, 73rd AHA Scientific Sessions, "Vascular Cell Growth: Basic Mechanisms", New Orleans, LA, November 12, 2000

Speaker, Medicine Grand Rounds, "Genetics and Pharmacogenomics of Unstable Coronary Syndromes", William Beaumont Hospital, Royal Oak, MI, December 6, 2000

Speaker, "New Mechanisms of Plaque Destabilization", Good Samaritan Hospital, Dayton, OH, December 13, 2000

Speaker, "Acute Coronary Syndromes: New and Views on Therapies", Weill Medical College of Cornell, New York, NY, December 18, 2000

Speaker, "News and Views on the Pathophysiology and Treatment of Acute Coronary Syndromes", Univ of PA Med Ctr, Philadelphia, PA, January 12, 2001

Speaker, Cardiology Grand Rounds, "Cardiovascular Disease: Advances in Treatment and Prevention – The Role of Antiplatelet Agents", UCSF Medical Center, San Francisco, CA
January 24, 2001

Speaker, Revolutionizing Ischemic Vascular Disease Management, "Beyond the Platelets: Plaque Stabilization-Survival Mechanisms of Abciximab", Washington Hospital Center, Washington, DC, January 31, 2001

Speaker, Tenth Annual Cardiovascular Conference at Beaver Creek, "Immediate Implications of the Human Genome Project for Cardiology", February 12, 2001 and "Platelet Polymorphisms", February 14, 2001, Beaver Creek, CO

Speaker, 2001 Cardiology Symposium, "Inflammation and Thrombosis: From Pathophysiology to Therapy", Raleigh, NC, February 17, 2001

Speaker, Palm Beach Forum, "An Essay on Longevity, Heart Disease and Your Gene Pool", Palm Beach, FL, March 2, 2001

Speaker, "The Role of Rac and NADPH Oxidase in Hypertension", Lerner Research Foundation, Cleveland Clinic Foundation, Cleveland, OH, March 6, 2001

Speaker, Heart Center Grand Rounds, "Eradication of Coronary Artery Disease by 2050", Cleveland Clinic Foundation, Cleveland, OH, March 7, 2001

Speaker, ACC 50th Annual Scientific Sessions, "Genetics of Cardiovascular Disease – Impact of Human Genome Project for Cardiovascular Disease", Orlando, FL, March 19, 2001

Speaker, Linking Internet Technology and Duke's Cardiovascular Databases to Explore Clinical Drug Development Questions, "Bringing Internet Access and Genomics to Cardiovascular Outcomes Research", Orlando, FL
March 19, 2001

Speaker, Medicine Conference, "Thrombotic Complications and Cardiovascular Disease", Durham Regional Hospital, Durham, NC, March 28, 2001

Speaker, Radiology Grand Rounds, "Cardiovascular Genomics and Molecular Imaging", Duke Univ Med Ctr, Durham, NC, March 29, 2001

Speaker, Experimental Biology 2001, "Platelet Glycoprotein (GP11a) Variants, Coronary Thromboembolism and Response to Aspirin", Orlando, FL, April 2, 2001

Speaker, 5th Annual Duke-Pinehurst Stent Symposium, Keynote Address: "The Human Genome Project-What Does it Mean to Cardiologists?", Pinehurst, NC, May 5, 2001

Speaker, Cardiology Grand Rounds, Columbia Univ, NY, NY
Speaker, Cardiology Grand Rounds, Westchester Medical Center, Valhalla, NY "Platelet Inhibition in Acute Coronary Syndromes: From Bench to Bedside", May 8, 2001

Speaker, Cardiology Grand Rounds, Tulsa Regional Medical Center, "Cardiovascular Disease: Advances in the Treatment and Prevention – The Role of Antiplatelet Agents", Tulsa, OK, June 27, 2001

Speaker, Diet, DNA and Methylation Processes and Health Workshop organized by the National Institute of Health: "DNA Methylation and Atherosclerosis", Bethesda, MD, August 7, 2001

Speaker, Cardiology Conference, University of Miami Hospital, Speaker, Cardiology Grand Rounds, Mt. Sinai Medical Center, "Therapeutics for Acute Coronary Syndromes – the Post CURE Era", Miami, FL, August 29-30, 2001

Speaker, Intervention 2001, "Pharmacogenetics", Atlanta, GA, September 6, 2001

Speaker, Margolis Lecture, Johns Hopkins University, "Elimination of Coronary Heart Disease by 2050", September 24, 2001

Speaker, Cardiology Grand Rounds, The Johns Hopkins Medical Center, "Atherosclerosis, From Genetics to Therapeutics", October 10, 2001

Speaker, Georgia Chapter Annual Scientific ACC Meeting, Savannah, GA, "Platelet Physiology, Pathology and Genetics in Acute Coronary Syndromes", October 20, 2001

Speaker, AMA Reporters Conference, San Francisco, CA, "Genetics of Heart Disease: Tailoring Treatment and Prevention", October 29, 2001

Speaker, Eli Lilly Satellite Symposium, "2001-A Year in Perspective – Spotlight on the Heart during 74th AHA Annual Scientific Sessions, "Pathogenesis of Plaque Instability: A Paradigm Shift in Concept", November 11, 2001

Speaker, Cardiology Grand Rounds, Gunderson Lutheran Medical Center, La Crosse, WI, "Managing Atherothrombosis: Implications of Recent Clinical Trials", November 28, 2001

Speaker, Cardiology Grand Rounds, University of Minnesota Hospital, Minneapolis, MN, "A New Standard of Care in Acute Coronary Syndromes", November 29, 2001

Speaker, Cardiology Grand Rounds, Mayo Clinic, Rochester, MN, "Platelet Control in Acute Coronary Syndromes, from Therapeutics to Pharmacogenetics", November 30, 2001

Speaker, Walter Reed Symposium, Womack Army Medical Center, Fayetteville, NC, "Antiplatelet Therapy", December 12, 2001

Speaker, Cardiology Grand Rounds, Albert Einstein University Montefiore Medical Center, Bronx, NY, "Searching for the Rosetta Stone of Atherosclerosis", January 29, 2002

Speaker, 11th Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, "Atherosclerosis: The Genomic Era", February 11, 2002

Speaker, Cardiology Grand Rounds, Baylor College of Medicine, Houston, TX, "Progress in Atherosclerosis and CAD: Genomics and Proteomics", February 21, 2002

Speaker, 12th Annual Cardiology Symposium, Halifax Regional Hospital, South Boston, VA, "Human Genetic Affect on Coronary Artery Disease", March 5, 2002

Speaker, Merck Platelets and Cardiovascular Treatments Symposium during 51st Annual ACC Scientific Sessions, Atlanta, GA, "Pride, Esprit", March 17, 2002

Speaker, Medicine Grand Rounds, Louisiana State University Medical Center, Shreveport, LA, "Genomics to Genetics – A Different Approach to Atherosclerosis", March 26, 2002

Speaker, Medicine Grand Rounds, Union Memorial Hospital, Baltimore, MD, "Atherosclerosis and Genetics", April 25, 2002

Speaker, 42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association Honolulu, HI, "Endothelial Function in Vascular Disease, April 26, 2002

Speaker, X Simposio Internacional de Cardiopatía Isquémica, Bilbao, Spain, "Implications of Human Genome in Cardiovascular Disease", May 22-24, 2002

Speaker, Bethesda, MD, "Beyond the Platelets: Plaque Stabilization-Survival Mechanisms of Abciximab", August 20, 2002

Speaker, Takoma Park, MD, "ACC/AHA Guideline Updates 2002", August 23, 2002

Speaker, "GPIIb/IIIa Inhibition and a Drug Eluting Stent", during European Society of Cardiology, Berlin, Germany, Sept. 1, 2002

Speaker, European Society of Cardiology, Berlin, Germany, "Current Understanding of the Pathophysiology of Arterial Thrombosis", Sept. 3, 2002

Speaker, Intervention 2002, Atlanta, GA, "Etiology of Atherosclerosis: A Genomic Look", Sept. 6, 2002

Speaker, TCT Symposium, Washington, DC, "Inflammation in PCI", Sept. 25, 2002, "Diagnosis and Therapeutic Approaches to ASCVD in the Genomics Era", Sept. 26, 2002

Speaker, Corazon Annual Conference, Naples, FL, "The Future of Cardiology", Oct. 2, 2002

Speaker, "Basic Mechanisms Underlying Plaque Stability", during American Heart Association meeting, Chicago, IL, Nov. 16, 2002

Speaker, Cardiology Grand Rounds, Univ of VA, Charlottesville, VA, "Translation of Scientific Discoveries on Atherosclerosis into Clinically Relevant Strategies", Dec. 3, 2002

Speaker, The Simon Dack Visiting Professorship, "Genetics of Coronary Artery Disease" and "Controversies in Cardiology: Detection of Unstable Plaque: What is Best Technique"? Mt. Sinai Medical Center, NY, NY, June 23, 2003

Speaker, Experts on the Evidence: Prevention and Management of Thrombus in Acute Coronary Syndrome, "Understanding the Healing Artery: From Thrombosis to Lesion Passivation", during European Society of Cardiology meeting, Vienna, Austria, Sept. 2, 2003

Co-Chair, Genetics of Cardiovascular Disease Roundtable, Pentagon City, VA, Sept 12-13, 2003

Speaker, "Diagnosis and Therapeutic Approaches to ASCVD in the Genomics Era", "A Primer of Genetics and Proteomics for the Cardiologist", "Theory Behind Stem Cells and Cardiovascular Repair". Discussant, "How and When Will Genetic Profiling Impact Patient Care?", "When and Which Gene Therapies Will Become Mainstream?", during Transcatheter Cardiovascular Therapeutics meeting, Washington, DC, Sept 15, 2003

Speaker, First Annual Shupar Naimi Lecture in Cardiology, "On the Memory of Chronic Illness: The Case for Atherosclerosis", Tufts New England Medical Center, Boston, MA, Sept 30, 2003

Speaker, Johns Hopkins Cardiology Update – 2003, "New Clues to Cardiovascular Aging", Captiva Island, FL, Oct 10, 2003

Speaker, "Bench: Stem Cell Plascity: Are Myogenesis and Angiogenesis Possible?", "The Aging Vasculature – Cellular Senescence and Atherogenesis", Session Moderator: Going Nano: To The Vessel and Beyond, during American Heart Association meetings, Orlando, FL, Nov 9-10, 2003

NHLBI, SCCOR Vascular Diseases in Research Priority Panel, Bethesda, MD, Dec 10-11, 2003

Speaker, Eighth Duke Advanced Interventional Cardiology Symposium, "Genomics of Cardiovascular Disease", Vail, CO, Jan 15-18, 2004

Speaker, Johns Hopkins GeneSTAR meeting, "Platelet Phenotyping and Quality Control Issues", Baltimore, MD, Mar 19, 2004

Speaker, Doris Duke Clinical Scientist meeting, "Progenitor Cell Based Therapeutic Strategies for Atherosclerosis", Cold Spring Harbor, NY, Mar 20-21, 2004

Speaker, 2nd Annual International Conference on NAD(P)H Oxidases (NoxII), "Rac1 Regulation of the Cardiovascular System", Pine Mt, GA, Mar 30-31, 2004

Speaker, Society of Vascular Surgery Translational Vascular Research: "From Bench to Bedside to Boardroom", "Bone Marrow Derived Pluripotential Cells in Atherosclerosis", Bethesda, MD, Apr 1, 2004

Speaker, Cardiology Grand Rounds, "Atherosclerosis: From Genomics to Clinic", University of Rochester Med Center, Rochester, NY, Apr 27-28, 2004

Speaker, The Frank N. Wilson Visiting Professor, Cardiology Grand Rounds, "Novel Clues on the Aging Risk in Atherosclerosis and ACS", Univ of Michigan Health System, Ann Arbor, MI, May 11, 2004

Speaker, Cardiology Grand Rounds, "Current Controversies in Acute Coronary Syndromes", Case Western Reserve University, Cleveland, OH, May 13, 2004

Speaker, Tulane-LSU Medicine Grand Rounds, "Vascular Progenitor Cells and Atherosclerosis", Tulane Univ Health Sci Center, New Orleans, LA, June 2, 2004

Speaker, 2004 Report Card on Interventional Coronary Management, "Defining the PCI Patient Who Benefits from GP IIb/IIIa Inhibition", Chicago, IL, June 12, 2004

Speaker, Columbia University Medical Center Medicine Grand Rounds, "Vascular Progenitor Cells and Atherosclerosis", New York, NY, July 7, 2004

Speaker, Medicine Grand Rounds, University of Arkansas for Medical Sciences, Richard V. Ebert Visiting Professor, "Vascular Progenitor Cells and Atherosclerosis", Little Rock, AR, July 15, 2004

Speaker, SingHealth Grand Rounds, "The Era of Cell Therapy for Cardiovascular Disease", Singapore National Heart Centre, Singapore, July 22, 2004

Speaker/Moderator, "Cardiovascular Genetics, Genomics, and Proteomics", Transcatheter Cardiovascular Therapeutics, Washington, DC, September 27, 2004

Speaker, "Gene Expression Studies of Atherosclerosis", American Heart Association Scientific Sessions, New Orleans, LA, November 7, 2004

Speaker, "The Era of Bone Marrow Derived Repair – Competent Cells for Atherosclerosis", NIA Stem Cells and Aging Meeting, Bethesda, MD, November 10, 2004

Speaker, "Functional Genomics", American Society of Hypertension, Inc., Naples, FL, January 15, 2005

Speaker, "Cell-Based Therapy: Myth or Reality", American College of Cardiology Scientific Sessions, Orlando, FL, March 8, 2005

Speaker, "Arterial Inflammation and Repair in Atherosclerosis and CAD", NYU Medical Center, NY, NY, March 22, 2005

Speaker, "Progenitor Cells in Cardiovascular Disease", Society of Vascular Surgery, Washington, DC, April 8, 2005

Speaker, "Cell Therapy Solutions for Arterial Disorders", American Society of Hypertension, San Francisco, CA, May 16, 2005

Speaker, "Cell Therapy Solutions for Arterial Disorders", Cardiology Grand Rounds, UCSF, San Francisco, CA, May 18, 2005

Speaker, "Arterial Homeostasis, Inflammation, and Erythropoietic Growth Factors", Amgen, Anemia: A Modifiable Risk Factor for Heart Disease" Roundtable, Boston, MA, July 15, 2005

Speaker, "Failure of Arterial Repair with Aging Leads to Atherosclerosis", Boston Medical Center, Boston, MA, September 13, 2005

Speaker, International Heart Forum Beijing 2005, "Aging, Stem Cells and Coronary Artery Disease", Beijing, China September 16, 2005

Speaker, National Institute on Aging, Nathan W. Shock Symposium "Stem Cells: Regenerative Medicine?" Arterial Repair, Atherosclerosis, Bone Marrow Problems", September 30, 2005

Speaker, AEHA, SHAPE Task Force Symposium, "Designer Genes: From Plaque to Attack-Introducing novel

Genomic and proteomic markers of atherosclerosis versus atherothrombosis", American Heart Association Scientific Sessions, Dallas, Texas, November 12, 2005

Speaker, Session-From Genome to Phenome: The Translational Biology of Cardiovascular Disease, "Genome Expressions Profiling", American Heart Association Scientific Sessions, Dallas, Texas, November 12, 2005

Speaker, Amgen, Anemia: A Modifiable Risk Factor for Heart Disease, "Anemia, Cytokines, and Bone Marrow Responses on Cardiovascular Function", American Heart Association Scientific Sessions, Dallas, Texas, November 12, 2005

Speaker, Session-Restenosis, Atherosclerosis, and Angiogenesis-Is There a Link?, "Stem Cells and Plaque Growth, American Heart Association Scientific Sessions, Dallas, Texas, November 13, 2005

Speaker, Lillehei Heart Institute, "Of Aging, Cellular Repair and Atherosclerosis", Minneapolis, MN, November 29, 2005

Speaker, Medical Grand Rounds, University of Miami Leonard M. Miller School of Medicine, "How to 'Enjoy your Steak and Eat it, too'". Miami, FL, June 30, 2006

Speaker, Medical Grand Rounds, "Educating Doctors: The International Era". University of Miami Leonard Miller School of Medicine. Miami, FL, October 3, 2006.

Speaker, Southeastern American Medical Student Association (AMSA): "Diversity in Medicine". Welcome and Introduction University of Miami Leonard Miller School of Medicine, Miami, FL. November 10, 2006.

Speaker, Nutrition, Fitness and Global Health Conference "How to Have Your Steak and Live to Enjoy It Too". UM Miller School of Medicine, Miami, FL, November 11, 2006.

Speaker, IBM and Scripps Telephone Conference, "Checkmate!" November 17, 2006.

Speaker, National Institutes of Health Angiogenesis in the Nervous System Workshop. "Aging of endothelial precursors". Bethesda, MD. December 12, 2006.

Keynote Speaker, 42nd Annual Postgraduate Course of Internal Medicine Update 2007. "How to have your steak and live to enjoy it, too". Miami, FL, January 23, 2007.

Speaker, 2007 Biotech Symposium. "New Jenner-ation", Miami, FL, January 28, 2007.

Speaker, 5th Annual Miami International Revascularization Summit. "How to have your steak and live to enjoy it". Miami, FL, February 9, 2007.

Speaker, Veterans' Affairs Medical Center Geriatric Institute Grand Rounds. "Endothelial Cell Therapy and Aging". Miami, FL, February 15, 2007.

Speaker, Rodney Howell Lecture. "*Generation G-for Genome-and the Legacy of the Boomers*". Miami, FL, February 23, 2007.

15th Annual Miriam Lemberg Visiting Professorship in Cardiovascular Disease Lecture Speaker, University of Miami Miller School of Medicine Department of Medicine Grand Rounds, "*Myocardial Infarction: From ST-Elevation to Genomics*." Miami, FL, March 7, 2007.

Speaker, Ochsner Basic Science in Clinical Medicine Lecture Series, "*The Genomics of Atherosclerosis*", New Orleans, LA March 13, 2007.

Speaker, Biology of Aging Seminar, "*Aging and the Heart*", Miami, FL, March 20, 2007.

Speaker, Preventive Cardiovascular Therapeutics Symposium, "*The Genomics of Atherosclerosis and CAD*", Coral Gables, FL, April 20, 2007.

Speaker, InterAmerican Society of Hypertension and Consortium for SE Hypertension Control, "Arterial Disease and Repair", May 5, 2007.

Speaker, "Synecor: A New Paradigm for Rapid Commercialization of Medical Terminology", Miami, FL, May 8, 2007.

Speaker, Cardiovascular Disease Forum Journal Club, "Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", Miami, FL, June 6, 2007.

Speaker, AHA-4th Symposium of the Burden of Therosclerotic Disease: Diagnosis and Therapy, "Burden of Atherothrombosis: Mechanisms and Pathology on Vascular Cell Morphology and Repair", New York City, NY, June 9, 2007.

Speaker, Baptist Hospital South Florida Cardiovascular Conference, "Genomics of Cardiovascular Disease", Miami, FL, September 20, 2007.

Speaker, Fundamentals of Translational Science, "At the leading edge of medicine: from genomic prevention to robotic surgical solutions", Miami, FL, September 21, 2007.

Speaker, South Miami Heart Center 2007 Comprehensive Cardiovascular Conference, "Cardiac Genomics", Coral Gables, FL, October 19, 2007.

Speaker, Neonatology 2007: Association of Administrators in Academic Pediatrics (AAP), "Vaccine, the best human prevention yet", Miami, FL, November 8, 2007.

Speaker, Veterans' Administration Geriatrics and Gerontology Grand Rounds July 2007-June 2008, "Aging: not just the passage of time", Miami, FL, February 21, 2008.

Editorial Activities:

Executive Editor, Journal of Antioxidant and Redox Research
Editorial Board, Biomedical Microdevices
Editorial Board, American Heart Journal
Editorial Board, Clinical and Translational Science
Editorial Board, Cardiology
Honorary Editorial Board, Stem Cells and Cloning: Advances and Applications

1984	NATO Scientific Award
1985	Clinical Research Fellowship Award, Medical University of South Carolina
1985	Diplomate, Educational Commission for Foreign Medical Graduates Examination
1986	Diplomate, Federation Licensing Examination
1990	The Johns Hopkins University, School of Medicine Basic Science Award for Postdoctoral Investigation.
1990	American Heart Association Fellowship Award
1991	Katz Prize Finalist, American Heart Association Clinician Scientist Award, Johns Hopkins University School of Medicine
1992	Syntax Scholars Program Award for Outstanding Achievement in Cardiovascular Research
1995	Established Investigator Award, American Heart Association
1996	Laureate, OSU Heart and Lung Institute Directorship Search
1997	John H. and Mildred C. Lumley Endowed Chair of Medicine
1997	Elected, American Society for Clinical Investigations
1999	Fellow, American College of Cardiology (FACC)
2002	Association of Black Cardiologists, Inc. Award for Commitment to Diversity and Cultural Enrichment in Medical Education
2004	Society of Scholars Johns Hopkins University
2006	Honorary Grand Marshall, Humane Society Walk
2007-8	Best Doctors in America Peer Recognition

VII. SERVICE

Administrative Committees:

University

Chair, Selective Investment Committee, OSU
 Member, University Human Subjects Review Steering Committee
 Chair appointed by the University President, Task Force for Restructuration of OSU College of Medicine
 Chair appointed by the University President, Senior Vice President and Dean Search, College of Medicine and Public Health Search Committee. Dr. Fred Sanfilippo laureate (Formerly Chair of the Department of Pathology at Johns Hopkins University)
 Duke Center for Genome Ethics, Law and Policy Steering Committee
 Duke Center for Genome Ethics, Law and Policy Director, Search Committee
 Duke Institute for Genome Sciences and Policy Steering Committee
 Duke Institute for Genome Sciences and Policy Director, Search Committee
 Duke Center for Bioinformatics and Computational Biology
 Director, Search Committee

Medical Center

Johns Hopkins University School of Medicine Director of Cardiology Search, laureate Kenneth Baughman
 Chair of the Search Committee, Director of Cardiothoracic Surgery, Dr. Robert Michler laureate (Formerly Cardiac Surgeon at Columbia University)
 Chair, Heart Center Task Force
 Chair, Chief of Gastroenterology Search Committee
 Member, Medical Center Leadership Council
 Molecular Medicine Coordinators Committee
 Member, Search Committee for Director of Division of Laboratory Animal Research (DLAR)

Member, Duke Comprehensive Cancer Center Steering Committee
 Member, Duke University Health System Board of Directors
 Member, Duke University Health System Executive Management Committee
 Member, Duke Executive Committee of the School of Medicine
 Member, Duke Medical Center Executive Committee
 Member, PDC Affairs Committee
 Member, PDC Administrative Board
 Member, Joint Liability Steering Committee
 Member, Scientific Advisory Group for The National Children's Study, Department of Pediatrics, Miller School of Medicine

Leadership Recruitment:

- 1997 Robert Michler, M.D.
Chief, Cardiothoracic Surgery
Ohio State University Medical Center
- 2000 Fred Sanfilippo, M.D., Ph.D.
Senior Vice President and Executive Dean for Health Sciences
Dean, College of Medicine and Public Health
CEO, Ohio State University Medical Center
- 2003 Anna Mae Diehl, M.D.
Chief, Division of Gastroenterology
Duke University Medical Center
- 2003 Nelson Chao, M.D.
Chief, Division of Cellular Therapy
Duke University Medical Center
- 2004 Pamela Douglas, M.D.
Chief, Division of Cardiology
Duke University Medical Center
- 2004 Nancy Rhodes, M.P.H.
Vice Chair, Administration, Financy & Business Strategy
Chief Financial Officer
Department of Medicine
Duke University Medical Center
- 2004 Monica Kraft, M.D.
Director, Asthma Center
Duke University Medical Center
- 2004 Geoffrey Ginsburg, M.D.
Director, IGSP Center for Genomic Medicine
Duke University Medical Center
- 2005 Paul Noble, M.D.
Chief, Division of Pulmonary, Allergy & Critical Care Medicine
Duke University Medical Center
- 2006 Julio Licinio, M.D.
Chair, Department of Psychiatry and Behavioral Sciences
University of Miami Leonard M. Miller School of Medicine
- 2006 William O'Neill, M.D.

Executive Dean for Clinical Affairs
University of Miami Leonard M. Miller School of Medicine

- 2006 Eli Gilboa, Ph.D.
Professor of Microbiology and Immunology
Sylvester Comprehensive Cancer Center
University of Miami Leonard M. Miller School of Medicine
- 2006 William Donelan
Vice President for Medical Administration and Chief Operating and
Strategy Officer
University of Miami Leonard M. Miller School of Medicine
- 2006 Joshua M Hare, M.D.
Professor and Chief of Cardiology
Director of Interdisciplinary Stem Cell Institute
Louis Lemberg Professor of Medicine
Assistant Dean of Research
University of Miami Leonard M. Miller School of Medicine
- 2006 Margaret Pericak-Vance, Ph.D.
Director, Institute of Human Genomics
Department of Human Genetics
University of Miami Leonard M. Miller School of Medicine
- 2006 Dr. Jeffery Vance, M.D., Ph.D.
Division of Human Genetics
Chairman of Department of Human Genetics
University of Miami Leonard M. Miller School of Medicine
- 2007 Ralph L. Sacco, M.D., M.S.
Chairman of the Department of Neurology
University of Miami Leonard M. Miller School of Medicine
- 2007 Sheri Keitz, M.D., Ph.D.
Associate Dean for Faculty Diversity and Development, University of
Miami Leonard M. Miller School of Medicine
Chief of Medicine, Miami VAMC
- 2007 Thomas M. Hooton, M.D.,
Director of the Institute for Women's Health
Associate Dean for Women's Health
Miami Leonard M. Miller School of Medicine
- 2007 Marc Lippman, M.D.
Chairman of the Department of Medicine
University of Miami Leonard M. Miller School of Medicine
- 2007 Bart Chernow, M.D
Vice President for Special Programs and Resource Strategy
University of Miami Leonard M. Miller School of Medicine
- 2007 Michele Chulick
Director of Hospital Operations and Associate Vice President
University of Miami Health System
- 2007 Diana D. Cardenas, M.D., M.H.A.

Chair of the Department of Rehabilitation Medicine
University of Miami Leonard M. Miller School of Medicine

2007

Michael A. Kolber, M.D., Ph.D.
Medical Directorship of the Comprehensive AIDS Program
University of Miami Leonard M. Miller School of Medicine

2007

Steven Falcone, M.D., M.B.A
Executive Clinical Dean for the Regional Campus
University of Miami Miller School of Medicine at Florida Atlantic University
Boca Raton, FL